idx,id,drug,disease,nodes,n_nodes,n_edges,n_paths,metapath,metapath_with_edges,metabolite,Drug_MeshID,node_names,drug_name,disease_name,metabolite_name,edges,question,metabolite_name_str
56,DB00994_MESH_D007634_1,DRUGBANK:DB00994,MESH:D007634,"['MESH:D009355', 'CHEBI:18111', 'GO:0006412', 'taxonomy:1280', 'MESH:D007634']",5,4,1,['Drug - ChemicalSubstance - BiologicalProcess - OrganismTaxon - Disease'],['Drug - decreases activity of - ChemicalSubstance - participates in - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:18111,MESH:D009355,"['neomycin', 'ribosomal RNA', 'translation', 'Staphylococcus aureus', 'Keratitis']",neomycin,Keratitis,['ribosomal RNA'],"['decreases activity of', 'participates in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug neomycin via its mechanism of action in treating the Disease Keratitis ?,ribosomal RNA
106,DB00602_MESH_D009855_1,DRUGBANK:DB00602,MESH:D009855,"['MESH:D007559', 'InterPro:IPR015680', 'CHEBI:17996', 'GO:0060081', 'MESH:D010243', 'taxonomy:6282', 'MESH:D009855']",7,6,1,['Drug - GeneFamily - ChemicalSubstance - BiologicalProcess - OrganismTaxon - Disease'],['Drug - increases activity of - GeneFamily - increases abundance of - ChemicalSubstance - participates in - BiologicalProcess - negatively regulates - OrganismTaxon - causes - Disease'],CHEBI:17996,MESH:D007559,"['ivermectin', 'Glutamate-Gated Chloride Channel', 'chloride ion', 'membrane hyperpolarization', 'Paralysis', 'Onchocerca volvulus', 'Infection by Onchocerca volvulus']",ivermectin,Infection by Onchocerca volvulus,['chloride ion'],"['increases activity of', 'increases abundance of', 'participates in', 'negatively regulates', 'causes']",Which biochemical entity is affected by the Drug ivermectin via its mechanism of action in treating the Disease Infection by Onchocerca volvulus ?,chloride ion
139,DB00983_MESH_D011656_1,DRUGBANK:DB00983,MESH:D011656,"['MESH:D000068759', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'UBERON:0002187', 'MESH:D011656']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - location of - Disease'],CHEBI:17489,MESH:D000068759,"['formoterol', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'terminal bronchiole', 'Pulmonary emphysema']",formoterol,Pulmonary emphysema,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'positively correlated with', 'located in', 'location of']",Which biochemical entity is affected by the Drug formoterol via its mechanism of action in treating the Disease Pulmonary emphysema ?,"3',5'-cyclic AMP"
172,DB06335_MESH_D003924_1,DRUGBANK:DB06335,MESH:D003924,"['MESH:C502994', 'UniProt:P27487', 'CHEBI:80270', 'GO:0030073', 'GO:0070091', 'HP:0003074', 'MESH:D003924']",7,7,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - negatively regulates - Protein - negatively regulates - ChemicalSubstance - negatively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:80270,MESH:C502994,"['saxagliptin', 'Dipeptidyl peptidase 4', 'Glucagon-like peptide 1', 'insulin secretion', 'glucagon secretion', 'Hyperglycemia', 'Diabetes Mellitus, Type 2']",saxagliptin,"Diabetes Mellitus, Type 2",['Glucagon-like peptide 1'],"['negatively regulates', 'negatively regulates', 'negatively regulates', 'positively correlated with', 'positively correlated with']","Which biochemical entity is affected by the Drug saxagliptin via its mechanism of action in treating the Disease Diabetes Mellitus, Type 2 ?",Glucagon-like peptide 1
234,DB01101_MESH_D013274_1,DRUGBANK:DB01101,MESH:D013274,"['MESH:D000069287', 'MESH:D005472', 'UniProt:P04818', 'GO:0090592', 'GO:0032774', 'CHEBI:63528', 'GO:0008283', 'MESH:D013274']",8,9,1,['Drug - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - produces - ChemicalSubstance - participates in - BiologicalProcess - positively correlated with - Disease'],CHEBI:63528,MESH:D000069287,"['Capecitabine', 'Fluorouracil', 'Thymidylate synthase', 'DNA synthesis involved in DNA replication', 'RNA biosynthetic process', 'Thymidine monophosphate', 'cell population proliferation', 'Malignant tumor of stomach']",Capecitabine,Malignant tumor of stomach,['Thymidine monophosphate'],"['produces', 'participates in', 'positively correlated with']",Which biochemical entity is affected by the Drug Capecitabine via its mechanism of action in treating the Disease Malignant tumor of stomach ?,Thymidine monophosphate
243,DB12417_MESH_D003924_1,DRUGBANK:DB12417,MESH:D003924,"['MESH:C583175', 'UniProt:P27487', 'CHEBI:80270', 'GO:0030073', 'GO:0070091', 'HP:0003074', 'MESH:D003924']",7,7,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - decreases abundance of - ChemicalSubstance - negatively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:80270,MESH:C583175,"['anagliptin', 'Dipeptidyl peptidase 4', 'Glucagon-like peptide 1', 'insulin secretion', 'glucagon secretion', 'Hyperglycemia', 'Diabetes Mellitus, Type 2']",anagliptin,"Diabetes Mellitus, Type 2",['Glucagon-like peptide 1'],"['decreases activity of', 'decreases abundance of', 'negatively regulates', 'positively correlated with', 'manifestation of']","Which biochemical entity is affected by the Drug anagliptin via its mechanism of action in treating the Disease Diabetes Mellitus, Type 2 ?",Glucagon-like peptide 1
250,DB00360_MESH_D010661_1,DRUGBANK:DB00360,MESH:D010661,"['MESH:C003402', 'UniProt:P00439', 'GO:0004505', 'CHEBI:28044', 'MESH:D010661']",5,4,1,['Drug - Protein - MolecularActivity - ChemicalSubstance - Disease'],['Drug - increases activity of - Protein - positively regulates - MolecularActivity - decreases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:28044,MESH:C003402,"['sapropterin', 'Phenylalanine-4-hydroxylase', 'phenylalanine 4-monooxygenase activity', 'phenylalanine', 'Classical phenylketonuria']",sapropterin,Classical phenylketonuria,['phenylalanine'],"['increases activity of', 'positively regulates', 'decreases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug sapropterin via its mechanism of action in treating the Disease Classical phenylketonuria ?,phenylalanine
251,DB00626_MESH_D007634_1,DRUGBANK:DB00626,MESH:D007634,"['MESH:D001414', 'CHEBI:17047', 'GO:0009273', 'taxonomy:1280', 'MESH:D007634']",5,4,1,['Drug - ChemicalSubstance - BiologicalProcess - OrganismTaxon - Disease'],['Drug - decreases abundance of - ChemicalSubstance - participates in - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:17047,MESH:D001414,"['bacitracin', 'all-trans-undecaprenyl diphosphate', 'peptidoglycan-based cell wall biogenesis', 'Staphylococcus aureus', 'Keratitis']",bacitracin,Keratitis,['all-trans-undecaprenyl diphosphate'],"['decreases abundance of', 'participates in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug bacitracin via its mechanism of action in treating the Disease Keratitis ?,all-trans-undecaprenyl diphosphate
252,DB00994_MESH_D014552_1,DRUGBANK:DB00994,MESH:D014552,"['MESH:D009355', 'CHEBI:18111', 'GO:0006412', 'taxonomy:562', 'MESH:D014552']",5,4,1,['Drug - ChemicalSubstance - BiologicalProcess - OrganismTaxon - Disease'],['Drug - decreases activity of - ChemicalSubstance - participates in - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:18111,MESH:D009355,"['neomycin', 'ribosomal RNA', 'translation', 'Escherichia coli', 'Urinary Tract Infections']",neomycin,Urinary Tract Infections,['ribosomal RNA'],"['decreases activity of', 'participates in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug neomycin via its mechanism of action in treating the Disease Urinary Tract Infections ?,ribosomal RNA
253,DB00994_MESH_D010032_1,DRUGBANK:DB00994,MESH:D010032,"['MESH:D009355', 'CHEBI:18111', 'GO:0006412', 'taxonomy:1280', 'MESH:D010032']",5,4,1,['Drug - ChemicalSubstance - BiologicalProcess - OrganismTaxon - Disease'],['Drug - decreases activity of - ChemicalSubstance - participates in - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:18111,MESH:D009355,"['neomycin', 'ribosomal RNA', 'translation', 'Staphylococcus aureus', 'Otitis externa']",neomycin,Otitis externa,['ribosomal RNA'],"['decreases activity of', 'participates in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug neomycin via its mechanism of action in treating the Disease Otitis externa ?,ribosomal RNA
254,DB00994_MESH_D014605_1,DRUGBANK:DB00994,MESH:D014605,"['MESH:D009355', 'CHEBI:18111', 'GO:0006412', 'taxonomy:562', 'MESH:D014605']",5,4,1,['Drug - ChemicalSubstance - BiologicalProcess - OrganismTaxon - Disease'],['Drug - decreases activity of - ChemicalSubstance - participates in - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:18111,MESH:D009355,"['neomycin', 'ribosomal RNA', 'translation', 'Escherichia coli', 'Uveitis']",neomycin,Uveitis,['ribosomal RNA'],"['decreases activity of', 'participates in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug neomycin via its mechanism of action in treating the Disease Uveitis ?,ribosomal RNA
255,DB00994_MESH_D006501_1,DRUGBANK:DB00994,MESH:D006501,"['MESH:D009355', 'CHEBI:18111', 'taxonomy:562', 'GO:0097272', 'HP:0001987', 'MESH:D006501']",6,5,1,['Drug - ChemicalSubstance - OrganismTaxon - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - decreases activity of - ChemicalSubstance - in taxon - OrganismTaxon - regulates - BiologicalProcess - prevents - PhenotypicFeature - positively correlated with - Disease'],CHEBI:18111,MESH:D009355,"['neomycin', 'ribosomal RNA', 'Escherichia coli', 'ammonium homeostasis', 'Hyperammonemia', 'Hepatic Encephalopathy']",neomycin,Hepatic Encephalopathy,['ribosomal RNA'],"['decreases activity of', 'in taxon', 'regulates', 'prevents', 'positively correlated with']",Which biochemical entity is affected by the Drug neomycin via its mechanism of action in treating the Disease Hepatic Encephalopathy ?,ribosomal RNA
305,DB00325_MESH_D006973_1,DRUGBANK:DB00325,MESH:D006973,"['MESH:D009599', 'CHEBI:16480', 'GO:0004383', 'MESH:D006152', 'GO:0044557', 'GO:0042311', 'HP:0032263', 'MESH:D006973']",8,7,1,['Drug - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - produces - ChemicalSubstance - positively regulates - BiologicalProcess - negatively regulates - PhenotypicFeature - positively correlated with - Disease'],CHEBI:16480,MESH:D009599,"['nitroprusside', 'nitric oxide', 'guanylate cyclase activity', 'Cyclic GMP', 'relaxation of smooth muscle', 'vasodilation', 'Increased blood pressure', 'Hypertension']",nitroprusside,Hypertension,['nitric oxide'],"['produces', 'positively regulates', 'negatively regulates', 'positively correlated with']",Which biochemical entity is affected by the Drug nitroprusside via its mechanism of action in treating the Disease Hypertension ?,nitric oxide
361,DB05812_MESH_D011471_6,DRUGBANK:DB05812,MESH:D011471,"['DB:DB05812', 'MESH:C000600172', 'UniProt:P18405', 'UniProt:P31213', 'UniProt:Q9H8P0', 'GO:0033764', 'CHEBI:16330', 'MESH:D011471']",8,9,1,['Drug - Protein - MolecularActivity - ChemicalSubstance - Disease'],['Drug - decreases activity of - Protein - positively regulates - MolecularActivity - produces - ChemicalSubstance - positively correlated with - Disease'],CHEBI:16330,DRUGBANK:DB05812,"['abiraterone acetate', 'delta4-abiraterone', '3-oxo-5-alpha-steroid 4-dehydrogenase 1', '3-oxo-5-alpha-steroid 4-dehydrogenase 2', 'Polyprenol reductase', 'steroid dehydrogenase activity, acting on the CH-OH group of donors, NAD or NADP as acceptor', '17β-hydroxy-5α-androstan-3-one', 'Malignant tumor of prostate']",abiraterone acetate,Malignant tumor of prostate,['17β-hydroxy-5α-androstan-3-one'],"['decreases activity of', 'positively regulates', 'produces', 'positively correlated with']",Which biochemical entity is affected by the Drug abiraterone acetate via its mechanism of action in treating the Disease Malignant tumor of prostate ?,17β-hydroxy-5α-androstan-3-one
407,DB00488_MESH_D010051_2,DRUGBANK:DB00488,MESH:D010051,"['MESH:D006585', 'CHEBI:73080', 'GO:0006305', 'CL:0001063', 'MESH:D010051']",5,4,1,['Drug - ChemicalSubstance - BiologicalProcess - Cell - Disease'],['Drug - has metabolite - ChemicalSubstance - positively regulates - BiologicalProcess - disrupts - Cell - causes - Disease'],CHEBI:73080,MESH:D006585,"['Altretamine', 'hemiaminal', 'DNA alkylation', 'tumor cell', 'Malignant tumor of ovary']",Altretamine,Malignant tumor of ovary,['hemiaminal'],"['has metabolite', 'positively regulates', 'disrupts', 'causes']",Which biochemical entity is affected by the Drug Altretamine via its mechanism of action in treating the Disease Malignant tumor of ovary ?,hemiaminal
427,DB09211_MESH_D013919_1,DRUGBANK:DB09211,MESH:D013919,"['DB:DB09211', 'UniProt:P43116', 'reactome:R-HSA-372790', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'MESH:D014661', 'MESH:D013919']",8,7,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - increases activity of - Protein - increases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:17489,DRUGBANK:DB09211,"['Limaprost', 'Prostaglandin E2 receptor EP2 subtype', 'Signaling by GPCR', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'vasoconstriction', 'Thromboangiitis obliterans']",Limaprost,Thromboangiitis obliterans,"[""3',5'-cyclic AMP""]","['increases activity of', 'increases abundance of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug Limaprost via its mechanism of action in treating the Disease Thromboangiitis obliterans ?,"3',5'-cyclic AMP"
455,DB00494_MESH_D010300_1,DRUGBANK:DB00494,MESH:D010300,"['MESH:C071192', 'UniProt:P21964', 'GO:0102084', 'CHEBI:15765', 'GO:0001963', 'MESH:D010300']",6,5,1,['Drug - Protein - MolecularActivity - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - positively regulates - MolecularActivity - decreases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - negatively correlated with - Disease'],CHEBI:15765,MESH:C071192,"['entacapone', 'Catechol O-methyltransferase', 'L-dopa O-methyltransferase activity', 'L-dopa', 'synaptic transmission, dopaminergic', ""Parkinson's disease""]",entacapone,Parkinson's disease,['L-dopa'],"['negatively regulates', 'positively regulates', 'decreases abundance of', 'positively correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug entacapone via its mechanism of action in treating the Disease Parkinson's disease ?,L-dopa
460,DB00165_MESH_D026681_1,DRUGBANK:DB00165,MESH:D026681,"['MESH:D011736', 'UniProt:O00764', 'GO:0008478', 'CHEBI:18405', 'MESH:D026681']",5,4,1,['Drug - Protein - MolecularActivity - ChemicalSubstance - Disease'],['Drug - interacts with - Protein - positively regulates - MolecularActivity - positively correlated with - ChemicalSubstance - negatively correlated with - Disease'],CHEBI:18405,MESH:D011736,"['pyridoxine', 'Pyridoxal kinase', 'pyridoxal kinase activity', ""pyridoxal 5'-phosphate"", 'Vitamin B6 deficiency']",pyridoxine,Vitamin B6 deficiency,"[""pyridoxal 5'-phosphate""]","['interacts with', 'positively regulates', 'positively correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug pyridoxine via its mechanism of action in treating the Disease Vitamin B6 deficiency ?,pyridoxal 5'-phosphate
468,DB00850_MESH_D012559_1,DRUGBANK:DB00850,MESH:D012559,"['MESH:D010546', 'UniProt:P14416', 'UniProt:P21728', 'GO:0014046', 'CHEBI:18243', 'UBERON:0001910', 'HP:0000746', 'MESH:D012559']",8,8,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - located in - GrossAnatomicalStructure - correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:18243,MESH:D010546,"['perphenazine', 'D(2) dopamine receptor', 'D(1A) dopamine receptor', 'dopamine secretion', 'Dopamine', 'medial forebrain bundle', 'Delusions', 'Schizophrenia']",perphenazine,Schizophrenia,['Dopamine'],"['decreases activity of', 'positively regulates', 'increases abundance of', 'located in', 'correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug perphenazine via its mechanism of action in treating the Disease Schizophrenia ?,Dopamine
579,DB05266_MESH_D001249_1,DRUGBANK:DB05266,MESH:D001249,"['MESH:C038366', 'InterPro:IPR043371', 'CHEBI:17489', 'GO:0006954', 'GO:0044557', 'MESH:D001249']",6,6,1,['Drug - GeneFamily - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - decreases activity of - GeneFamily - decreases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:17489,MESH:C038366,"['Ibudilast', ""cAMP-specific 3',5'-cyclic phosphodiesterase 4"", ""3',5'-cyclic AMP"", 'inflammatory response', 'relaxation of smooth muscle', 'Asthma']",Ibudilast,Asthma,"[""3',5'-cyclic AMP""]","['decreases activity of', 'decreases abundance of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug Ibudilast via its mechanism of action in treating the Disease Asthma ?,"3',5'-cyclic AMP"
658,DB06823_MESH_D003555_1,DRUGBANK:DB06823,MESH:D003555,"['MESH:D008625', 'CHEBI:17376', 'HP:0033067', 'HP:0000787', 'MESH:D003555']",5,5,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - decreases abundance of - ChemicalSubstance - causes - PhenotypicFeature - manifestation of - Disease'],CHEBI:17376,MESH:D008625,"['Tiopronin', 'cystine', 'Cystine crystalluria', 'Nephrolithiasis', 'Cystinuria']",Tiopronin,Cystinuria,['cystine'],"['decreases abundance of', 'causes', 'manifestation of']",Which biochemical entity is affected by the Drug Tiopronin via its mechanism of action in treating the Disease Cystinuria ?,cystine
659,DB00930_MESH_D006937_1,DRUGBANK:DB00930,MESH:D006937,"['MESH:D000069472', 'CHEBI:47774', 'MESH:D006937']",3,2,1,['Drug - ChemicalSubstance - Disease'],['Drug - decreases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:47774,MESH:D000069472,"['colesevelam', 'low-density lipoprotein cholesterol', 'Hypercholesterolemia']",colesevelam,Hypercholesterolemia,['low-density lipoprotein cholesterol'],"['decreases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug colesevelam via its mechanism of action in treating the Disease Hypercholesterolemia ?,low-density lipoprotein cholesterol
687,DB00203_MESH_D007172_2,DRUGBANK:DB00203,MESH:D007172,"['MESH:D000068677', 'UniProt:O76074', 'CHEBI:16356', 'GO:0044557', 'GO:0008015', 'GO:0043084', 'MESH:D007172']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - decreases activity of - Protein - decreases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:16356,MESH:D000068677,"['Sildenafil', ""cGMP-specific 3',5'-cyclic phosphodiesterase"", ""cyclic guanosine 3',5' monophosphate"", 'relaxation of smooth muscle', 'Blood circulation', 'Penile erection', 'Impotence']",Sildenafil,Impotence,"[""cyclic guanosine 3',5' monophosphate""]","['decreases activity of', 'decreases abundance of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug Sildenafil via its mechanism of action in treating the Disease Impotence ?,"cyclic guanosine 3',5' monophosphate"
688,DB00203_MESH_D000081029_1,DRUGBANK:DB00203,MESH:D000081029,"['MESH:D000068677', 'UniProt:O76074', 'CHEBI:16356', 'GO:0044557', 'GO:0042311', 'GO:0008217', 'MESH:D000081029']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - decreases activity of - Protein - decreases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - positively correlated with - Disease'],CHEBI:16356,MESH:D000068677,"['Sildenafil', ""cGMP-specific 3',5'-cyclic phosphodiesterase"", ""cyclic guanosine 3',5' monophosphate"", 'relaxation of smooth muscle', 'vasodilation', 'Blood Pressure', 'Pulmonary arterial hypertension']",Sildenafil,Pulmonary arterial hypertension,"[""cyclic guanosine 3',5' monophosphate""]","['decreases activity of', 'decreases abundance of', 'positively regulates', 'positively correlated with']",Which biochemical entity is affected by the Drug Sildenafil via its mechanism of action in treating the Disease Pulmonary arterial hypertension ?,"cyclic guanosine 3',5' monophosphate"
694,DB01064_MESH_D006323_1,DRUGBANK:DB01064,MESH:D006323,"['MESH:D007545', 'UniProt:P08588', 'UniProt:P07550', 'UniProt:P13945', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0086003', 'MESH:D006323']",8,9,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - increases activity of - Protein - increases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:17489,MESH:D007545,"['Isoprenaline', 'Beta-1 adrenergic receptor', 'Beta-2 adrenergic receptor', 'Beta-3 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'Cardiac muscle cell contraction', 'Cardiac arrest']",Isoprenaline,Cardiac arrest,"[""3',5'-cyclic AMP""]","['increases activity of', 'increases abundance of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug Isoprenaline via its mechanism of action in treating the Disease Cardiac arrest ?,"3',5'-cyclic AMP"
695,DB01064_MESH_D054537_1,DRUGBANK:DB01064,MESH:D054537,"['MESH:D007545', 'UniProt:P08588', 'UniProt:P07550', 'UniProt:P13945', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0086003', 'MESH:D054537']",8,9,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - increases activity of - Protein - increases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:17489,MESH:D007545,"['Isoprenaline', 'Beta-1 adrenergic receptor', 'Beta-2 adrenergic receptor', 'Beta-3 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'Cardiac muscle cell contraction', 'Atrioventricular block']",Isoprenaline,Atrioventricular block,"[""3',5'-cyclic AMP""]","['increases activity of', 'increases abundance of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug Isoprenaline via its mechanism of action in treating the Disease Atrioventricular block ?,"3',5'-cyclic AMP"
696,DB01064_MESH_D002303_1,DRUGBANK:DB01064,MESH:D002303,"['MESH:D007545', 'UniProt:P08588', 'UniProt:P07550', 'UniProt:P13945', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0060047', 'MESH:D002303']",8,9,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - increases activity of - Protein - increases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:17489,MESH:D007545,"['Isoprenaline', 'Beta-1 adrenergic receptor', 'Beta-2 adrenergic receptor', 'Beta-3 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'heart contraction', 'Low cardiac output syndrome']",Isoprenaline,Low cardiac output syndrome,"[""3',5'-cyclic AMP""]","['increases activity of', 'increases abundance of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug Isoprenaline via its mechanism of action in treating the Disease Low cardiac output syndrome ?,"3',5'-cyclic AMP"
698,DB01064_MESH_D012769_1,DRUGBANK:DB01064,MESH:D012769,"['MESH:D007545', 'UniProt:P08588', 'UniProt:P07550', 'UniProt:P13945', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0060047', 'HP:0033532', 'MESH:D012769']",9,10,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - increases activity of - Protein - increases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - negatively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:17489,MESH:D007545,"['Isoprenaline', 'Beta-1 adrenergic receptor', 'Beta-2 adrenergic receptor', 'Beta-3 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'heart contraction', 'Decreased cardiac output', 'Hypovolemic shock']",Isoprenaline,Hypovolemic shock,"[""3',5'-cyclic AMP""]","['increases activity of', 'increases abundance of', 'positively regulates', 'negatively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug Isoprenaline via its mechanism of action in treating the Disease Hypovolemic shock ?,"3',5'-cyclic AMP"
720,DB01397_MESH_D005334_1,DRUGBANK:DB01397,MESH:D005334,"['MESH:C496892', 'UniProt:P23219', 'UniProt:P35354', 'CHEBI:15551', 'MESH:D005334']",5,5,1,['Drug - Protein - ChemicalSubstance - Disease'],['Drug - decreases activity of - Protein - increases abundance of - ChemicalSubstance - positively regulates - Disease'],CHEBI:15551,MESH:C496892,"['Magnesium salicylate', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Prostaglandin E2', 'Fever']",Magnesium salicylate,Fever,['Prostaglandin E2'],"['decreases activity of', 'increases abundance of', 'positively regulates']",Which biochemical entity is affected by the Drug Magnesium salicylate via its mechanism of action in treating the Disease Fever ?,Prostaglandin E2
754,DB09208_MESH_D006073_1,DRUGBANK:DB09208,MESH:D006073,"['MESH:C031545', 'CHEBI:27226', 'HP:0002149', 'MESH:D006073']",4,3,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - decreases abundance of - ChemicalSubstance - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:27226,MESH:C031545,"['pegloticase', 'uric acid', 'Hyperuricemia', 'Gout']",pegloticase,Gout,['uric acid'],"['decreases abundance of', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug pegloticase via its mechanism of action in treating the Disease Gout ?,uric acid
757,DB01698_MESH_D001206_1,DRUGBANK:DB01698,MESH:D001206,"['MESH:D012431', 'CHEBI:21241', 'MESH:D001205', 'MESH:D001206']",4,3,1,['Drug - ChemicalSubstance - Disease'],['Drug - increases activity of - ChemicalSubstance - negatively correlated with - Disease'],CHEBI:21241,MESH:D012431,"['Rutin', 'vitamin C', 'ascorbic acid', 'Ascorbic acid deficiency']",Rutin,Ascorbic acid deficiency,['vitamin C'],"['increases activity of', 'negatively correlated with']",Which biochemical entity is affected by the Drug Rutin via its mechanism of action in treating the Disease Ascorbic acid deficiency ?,vitamin C
759,DB01166_MESH_D007383_1,DRUGBANK:DB01166,MESH:D007383,"['MESH:C045645', 'UniProt:Q14432', 'GO:0004115', 'CHEBI:17489', 'MESH:D017868', 'GO:0070527', 'GO:0042311', 'MESH:D007383']",8,8,1,['Drug - Protein - MolecularActivity - ChemicalSubstance - GeneFamily - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - positively regulates - MolecularActivity - decreases abundance of - ChemicalSubstance - increases activity of - GeneFamily - negatively correlated with - BiologicalProcess - negatively correlated with - Disease'],CHEBI:17489,MESH:C045645,"['cilostazol', ""cGMP-inhibited 3',5'-cyclic phosphodiesterase A"", ""3',5'-cyclic-AMP phosphodiesterase activity"", ""3',5'-cyclic AMP"", 'Cyclic AMP-Dependent Protein Kinases', 'Platelet aggregation', 'vasodilation', 'Intermittent claudication']",cilostazol,Intermittent claudication,"[""3',5'-cyclic AMP""]","['negatively regulates', 'positively regulates', 'decreases abundance of', 'increases activity of', 'negatively correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug cilostazol via its mechanism of action in treating the Disease Intermittent claudication ?,"3',5'-cyclic AMP"
771,DB00257_MESH_D002181_1,DRUGBANK:DB00257,MESH:D002181,"['MESH:D003022', 'UniProt:P10613', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'MESH:D002463', 'taxonomy:237561', 'MESH:D002181']",8,7,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - CellularComponent - PhenotypicFeature - OrganismTaxon - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - produces - ChemicalSubstance - located in - CellularComponent - regulates - PhenotypicFeature - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:D003022,"['clotrimazole', 'Lanosterol 14-alpha-demethylase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Cell Membrane Permeability', 'Candida albicans SC5314', 'Candidiasis, Vulvovaginal']",clotrimazole,"Candidiasis, Vulvovaginal",['ergosterol'],"['negatively regulates', 'positively regulates', 'produces', 'located in', 'regulates', 'in taxon', 'causes']","Which biochemical entity is affected by the Drug clotrimazole via its mechanism of action in treating the Disease Candidiasis, Vulvovaginal ?",ergosterol
772,DB00257_MESH_D003963_1,DRUGBANK:DB00257,MESH:D003963,"['MESH:D003022', 'UniProt:P10613', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'MESH:D002463', 'taxonomy:237561', 'MESH:D003963']",8,7,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - CellularComponent - PhenotypicFeature - OrganismTaxon - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - produces - ChemicalSubstance - located in - CellularComponent - regulates - PhenotypicFeature - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:D003022,"['clotrimazole', 'Lanosterol 14-alpha-demethylase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Cell Membrane Permeability', 'Candida albicans SC5314', 'Diaper Rash']",clotrimazole,Diaper Rash,['ergosterol'],"['negatively regulates', 'positively regulates', 'produces', 'located in', 'regulates', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug clotrimazole via its mechanism of action in treating the Disease Diaper Rash ?,ergosterol
773,DB00257_MESH_D002179_1,DRUGBANK:DB00257,MESH:D002179,"['MESH:D003022', 'UniProt:P10613', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'MESH:D002463', 'taxonomy:237561', 'MESH:D002179']",8,7,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - CellularComponent - PhenotypicFeature - OrganismTaxon - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - produces - ChemicalSubstance - located in - CellularComponent - regulates - PhenotypicFeature - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:D003022,"['clotrimazole', 'Lanosterol 14-alpha-demethylase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Cell Membrane Permeability', 'Candida albicans SC5314', 'Candidiasis, Cutaneous']",clotrimazole,"Candidiasis, Cutaneous",['ergosterol'],"['negatively regulates', 'positively regulates', 'produces', 'located in', 'regulates', 'in taxon', 'causes']","Which biochemical entity is affected by the Drug clotrimazole via its mechanism of action in treating the Disease Candidiasis, Cutaneous ?",ergosterol
774,DB00257_MESH_D002180_1,DRUGBANK:DB00257,MESH:D002180,"['MESH:D003022', 'UniProt:P10613', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'MESH:D002463', 'taxonomy:237561', 'MESH:D002180']",8,7,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - CellularComponent - PhenotypicFeature - OrganismTaxon - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - produces - ChemicalSubstance - located in - CellularComponent - regulates - PhenotypicFeature - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:D003022,"['clotrimazole', 'Lanosterol 14-alpha-demethylase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Cell Membrane Permeability', 'Candida albicans SC5314', 'Candidiasis, Oral']",clotrimazole,"Candidiasis, Oral",['ergosterol'],"['negatively regulates', 'positively regulates', 'produces', 'located in', 'regulates', 'in taxon', 'causes']","Which biochemical entity is affected by the Drug clotrimazole via its mechanism of action in treating the Disease Candidiasis, Oral ?",ergosterol
775,DB00257_MESH_D014008_1,DRUGBANK:DB00257,MESH:D014008,"['MESH:D003022', 'CHEBI:16933', 'GO:0030445', 'taxonomy:237561', 'MESH:D014008']",5,4,1,['Drug - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - disrupts - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:D003022,"['clotrimazole', 'ergosterol', 'yeast-form cell wall', 'Candida albicans SC5314', 'Tinea Pedis']",clotrimazole,Tinea Pedis,['ergosterol'],"['disrupts', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug clotrimazole via its mechanism of action in treating the Disease Tinea Pedis ?,ergosterol
776,DB00257_MESH_D014010_1,DRUGBANK:DB00257,MESH:D014010,"['MESH:D003022', 'UniProt:P10613', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'MESH:D002463', 'taxonomy:237561', 'MESH:D014010']",8,7,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - CellularComponent - PhenotypicFeature - OrganismTaxon - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - produces - ChemicalSubstance - located in - CellularComponent - regulates - PhenotypicFeature - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:D003022,"['clotrimazole', 'Lanosterol 14-alpha-demethylase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Cell Membrane Permeability', 'Candida albicans SC5314', 'Tinea Versicolor']",clotrimazole,Tinea Versicolor,['ergosterol'],"['negatively regulates', 'positively regulates', 'produces', 'located in', 'regulates', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug clotrimazole via its mechanism of action in treating the Disease Tinea Versicolor ?,ergosterol
821,DB00211_MESH_D007024_1,DRUGBANK:DB00211,MESH:D007024,"['MESH:D008879', 'CHEBI:73248', 'UniProt:P35348', 'UniProt:P35368', 'GO:0006939', 'HP:0032263', 'MESH:D007024']",7,7,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - positively regulates - BiologicalProcess - positively regulates - PhenotypicFeature - negatively correlated with - Disease'],CHEBI:73248,MESH:D008879,"['Midodrine', 'Deglymidodrine', 'Alpha-1A adrenergic receptor', 'Alpha-1B adrenergic receptor', 'smooth muscle contraction', 'Increased blood pressure', 'Orthostatic hypotension']",Midodrine,Orthostatic hypotension,['Deglymidodrine'],"['has metabolite', 'increases activity of', 'positively regulates', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug Midodrine via its mechanism of action in treating the Disease Orthostatic hypotension ?,Deglymidodrine
826,DB00458_MESH_D053206_1,DRUGBANK:DB00458,MESH:D053206,"['MESH:D007099', 'InterPro:IPR000995', 'CHEBI:15355', 'UBERON:0000381', 'GO:0060073', 'MESH:D053206']",6,5,1,['Drug - GeneFamily - ChemicalSubstance - GrossAnatomicalStructure - BiologicalProcess - Disease'],['Drug - decreases activity of - GeneFamily - positively correlated with - ChemicalSubstance - positively regulates - GrossAnatomicalStructure - positively regulates - BiologicalProcess - manifestation of - Disease'],CHEBI:15355,MESH:D007099,"['Imipramine', 'Muscarinic acetylcholine receptor family', 'acetylcholine', 'Urinary bladder detrusor smooth muscle', 'Micturition', 'Nocturnal enuresis']",Imipramine,Nocturnal enuresis,['acetylcholine'],"['decreases activity of', 'positively correlated with', 'positively regulates', 'positively regulates', 'manifestation of']",Which biochemical entity is affected by the Drug Imipramine via its mechanism of action in treating the Disease Nocturnal enuresis ?,acetylcholine
894,DB06710_MESH_D005058_1,DRUGBANK:DB06710,MESH:D005058,"['MESH:D008777', 'UniProt:P10275', 'GO:0060742', 'GO:0048808', 'GO:0008584', 'GO:0019102', 'GO:0007283', 'CHEBI:17347', 'MESH:D005058']",9,12,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - increases activity of - Protein - positively regulates - BiologicalProcess - positively correlated with - ChemicalSubstance - negatively correlated with - Disease'],CHEBI:17347,MESH:D008777,"['methyltestosterone', 'Androgen receptor', 'Epithelial cell differentiation involved in prostate gland development', 'Male genitalia morphogenesis', 'Male gonad development', 'Male somatic sex determination', 'Spermatogenesis', 'testosterone', 'Eunuchism']",methyltestosterone,Eunuchism,['testosterone'],"['increases activity of', 'positively regulates', 'positively correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug methyltestosterone via its mechanism of action in treating the Disease Eunuchism ?,testosterone
904,DB00850_MESH_D012559_2,DRUGBANK:DB00850,MESH:D012559,"['MESH:D011346', 'UniProt:P14416', 'GO:0014046', 'CHEBI:18243', 'MESH:D012559']",5,4,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:18243,MESH:D011346,"['prochlorperazine', 'D(2) dopamine receptor', 'dopamine secretion', 'Dopamine', 'Schizophrenia']",prochlorperazine,Schizophrenia,['Dopamine'],"['decreases activity of', 'positively regulates', 'increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug prochlorperazine via its mechanism of action in treating the Disease Schizophrenia ?,Dopamine
1003,DB09045_MESH_D003924_1,DRUGBANK:DB09045,MESH:D003924,"['MESH:C555680', 'UniProt:P43220', 'CHEBI:80270', 'GO:0030073', 'GO:0070091', 'HP:0003074', 'MESH:D003924']",7,7,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - increases activity of - Protein - positively correlated with - ChemicalSubstance - negatively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:80270,MESH:C555680,"['Dulaglutide', 'Glucagon-like peptide 1 receptor', 'Glucagon-like peptide 1', 'insulin secretion', 'glucagon secretion', 'Hyperglycemia', 'Diabetes Mellitus, Type 2']",Dulaglutide,"Diabetes Mellitus, Type 2",['Glucagon-like peptide 1'],"['increases activity of', 'positively correlated with', 'negatively regulates', 'positively correlated with', 'manifestation of']","Which biochemical entity is affected by the Drug Dulaglutide via its mechanism of action in treating the Disease Diabetes Mellitus, Type 2 ?",Glucagon-like peptide 1
1006,DB02701_MESH_D010383_1,DRUGBANK:DB02701,MESH:D010383,"['MESH:D009536', 'CHEBI:15940', 'HP:0100497', 'MESH:D010383']",4,3,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - correlated with - ChemicalSubstance - negatively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:15940,MESH:D009536,"['nicotinamide', 'Nicotinic acid', 'Vitamin B3 deficiency', 'Pellagra']",nicotinamide,Pellagra,['Nicotinic acid'],"['correlated with', 'negatively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug nicotinamide via its mechanism of action in treating the Disease Pellagra ?,Nicotinic acid
1027,DB00641_MESH_D006937_1,DRUGBANK:DB00641,MESH:D006937,"['MESH:D019821', 'CHEBI:169041', 'UniProt:P04035', 'GO:0006695', 'MESH:D002784', 'MESH:D006937']",6,5,1,['Drug - ChemicalSubstance - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - Disease'],CHEBI:169041,MESH:D019821,"['Simvastatin', 'simvastatin hydroxy acid', '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'cholesterol biosynthetic process', 'Cholesterol', 'Hypercholesterolemia']",Simvastatin,Hypercholesterolemia,['simvastatin hydroxy acid'],"['has metabolite', 'positively correlated with']",Which biochemical entity is affected by the Drug Simvastatin via its mechanism of action in treating the Disease Hypercholesterolemia ?,simvastatin hydroxy acid
1028,DB00641_MESH_D006950_1,DRUGBANK:DB00641,MESH:D006950,"['MESH:D019821', 'CHEBI:169041', 'UniProt:P04035', 'GO:0006695', 'UniProt:P06858', 'GO:0019433', 'MESH:D002784', 'MESH:D014280', 'MESH:D006950']",9,9,1,['Drug - ChemicalSubstance - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - Disease'],CHEBI:169041,MESH:D019821,"['Simvastatin', 'simvastatin hydroxy acid', '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'cholesterol biosynthetic process', 'Lipoprotein lipase', 'triglyceride catabolic process', 'Cholesterol', 'Triglycerides', 'Hyperlipidemia, Familial Combined']",Simvastatin,"Hyperlipidemia, Familial Combined",['simvastatin hydroxy acid'],"['has metabolite', 'positively correlated with']","Which biochemical entity is affected by the Drug Simvastatin via its mechanism of action in treating the Disease Hyperlipidemia, Familial Combined ?",simvastatin hydroxy acid
1029,DB00641_MESH_D015228_1,DRUGBANK:DB00641,MESH:D015228,"['MESH:D019821', 'CHEBI:169041', 'UniProt:P06858', 'GO:0019433', 'MESH:D014280', 'MESH:D015228']",6,5,1,['Drug - ChemicalSubstance - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - Disease'],CHEBI:169041,MESH:D019821,"['Simvastatin', 'simvastatin hydroxy acid', 'Lipoprotein lipase', 'triglyceride catabolic process', 'Triglycerides', 'Hypertriglyceridemia']",Simvastatin,Hypertriglyceridemia,['simvastatin hydroxy acid'],"['has metabolite', 'positively correlated with']",Which biochemical entity is affected by the Drug Simvastatin via its mechanism of action in treating the Disease Hypertriglyceridemia ?,simvastatin hydroxy acid
1030,DB00641_MESH_D052456_1,DRUGBANK:DB00641,MESH:D052456,"['MESH:D019821', 'CHEBI:169041', 'UniProt:P02647', 'GO:0034380', 'MESH:D008076', 'MESH:D052456']",6,5,1,['Drug - ChemicalSubstance - Disease'],['Drug - has metabolite - ChemicalSubstance - negatively correlated with - Disease'],CHEBI:169041,MESH:D019821,"['Simvastatin', 'simvastatin hydroxy acid', 'Apolipoprotein A-I', 'high-density lipoprotein particle assembly', 'Cholesterol, HDL', 'Hypoalphalipoproteinemia']",Simvastatin,Hypoalphalipoproteinemia,['simvastatin hydroxy acid'],"['has metabolite', 'negatively correlated with']",Which biochemical entity is affected by the Drug Simvastatin via its mechanism of action in treating the Disease Hypoalphalipoproteinemia ?,simvastatin hydroxy acid
1031,DB00641_MESH_D006952_1,DRUGBANK:DB00641,MESH:D006952,"['MESH:D019821', 'CHEBI:169041', 'UniProt:P04035', 'UniProt:P02647', 'GO:0006695', 'UniProt:P06858', 'GO:0019433', 'GO:0034380', 'MESH:D002784', 'MESH:D014280', 'MESH:D008076', 'MESH:D006952']",12,13,1,['Drug - ChemicalSubstance - Disease'],['Drug - has metabolite - ChemicalSubstance - negatively correlated with - Disease'],CHEBI:169041,MESH:D019821,"['Simvastatin', 'simvastatin hydroxy acid', '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'Apolipoprotein A-I', 'cholesterol biosynthetic process', 'Lipoprotein lipase', 'triglyceride catabolic process', 'high-density lipoprotein particle assembly', 'Cholesterol', 'Triglycerides', 'Cholesterol, HDL', 'Hyperlipoproteinemia Type III']",Simvastatin,Hyperlipoproteinemia Type III,['simvastatin hydroxy acid'],"['has metabolite', 'negatively correlated with']",Which biochemical entity is affected by the Drug Simvastatin via its mechanism of action in treating the Disease Hyperlipoproteinemia Type III ?,simvastatin hydroxy acid
1032,DB00641_MESH_D020521_1,DRUGBANK:DB00641,MESH:D020521,"['MESH:D019821', 'CHEBI:169041', 'UniProt:P04035', 'GO:0006695', 'MESH:D002784', 'HP:0002621', 'MESH:D020521']",7,6,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:169041,MESH:D019821,"['Simvastatin', 'simvastatin hydroxy acid', '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'cholesterol biosynthetic process', 'Cholesterol', 'Atherosclerosis', 'Stroke']",Simvastatin,Stroke,['simvastatin hydroxy acid'],"['has metabolite', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug Simvastatin via its mechanism of action in treating the Disease Stroke ?,simvastatin hydroxy acid
1033,DB00641_MESH_D001161_1,DRUGBANK:DB00641,MESH:D001161,"['MESH:D019821', 'CHEBI:169041', 'UniProt:P04035', 'GO:0006695', 'MESH:D002784', 'UBERON:0001637', 'MESH:D001161']",7,6,1,['Drug - ChemicalSubstance - GrossAnatomicalStructure - Disease'],['Drug - has metabolite - ChemicalSubstance - located in - GrossAnatomicalStructure - location of - Disease'],CHEBI:169041,MESH:D019821,"['Simvastatin', 'simvastatin hydroxy acid', '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'cholesterol biosynthetic process', 'Cholesterol', 'artery', 'Arteriosclerosis']",Simvastatin,Arteriosclerosis,['simvastatin hydroxy acid'],"['has metabolite', 'located in', 'location of']",Which biochemical entity is affected by the Drug Simvastatin via its mechanism of action in treating the Disease Arteriosclerosis ?,simvastatin hydroxy acid
1044,DB01158_MESH_D014693_1,DRUGBANK:DB01158,MESH:D014693,"['MESH:C045166', 'UniProt:P05023', 'GO:0006813', 'CHEBI:29103', 'HP:0011675', 'MESH:D014693']",6,5,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - positively correlated with - ChemicalSubstance - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:29103,MESH:C045166,"['bretylium', 'Sodium/potassium-transporting ATPase subunit alpha-1', 'potassium ion transport', 'Potassium(1+)', 'Arrhythmia', 'Ventricular fibrillation']",bretylium,Ventricular fibrillation,['Potassium(1+)'],"['decreases activity of', 'positively regulates', 'positively correlated with', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug bretylium via its mechanism of action in treating the Disease Ventricular fibrillation ?,Potassium(1+)
1076,DB00938_MESH_D011656_1,DRUGBANK:DB00938,MESH:D011656,"['MESH:D000068299', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'UBERON:0002185', 'MESH:D011656']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - affected by - Disease'],CHEBI:17489,MESH:D000068299,"['salmeterol', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'bronchus', 'Pulmonary emphysema']",salmeterol,Pulmonary emphysema,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'positively correlated with', 'located in', 'affected by']",Which biochemical entity is affected by the Drug salmeterol via its mechanism of action in treating the Disease Pulmonary emphysema ?,"3',5'-cyclic AMP"
1104,DB00461_MESH_D010003_1,DRUGBANK:DB00461,MESH:D010003,"['MESH:D000077430', 'CHEBI:35628', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'MESH:D011453', 'HP:0001386', 'HP:0002829', 'MESH:D010003']",9,10,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - produces - ChemicalSubstance - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:35628,MESH:D000077430,"['Nabumetone', '(6-methoxy-2-naphthyl)acetic acid', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'Prostaglandins', 'Joint swelling', 'Arthralgia', 'Osteoarthritis']",Nabumetone,Osteoarthritis,['(6-methoxy-2-naphthyl)acetic acid'],"['produces', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug Nabumetone via its mechanism of action in treating the Disease Osteoarthritis ?,(6-methoxy-2-naphthyl)acetic acid
1105,DB00461_MESH_D001172_1,DRUGBANK:DB00461,MESH:D001172,"['MESH:D000077430', 'CHEBI:35628', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'MESH:D011453', 'HP:0001386', 'HP:0002829', 'MESH:D001172']",9,10,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - produces - ChemicalSubstance - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:35628,MESH:D000077430,"['Nabumetone', '(6-methoxy-2-naphthyl)acetic acid', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'Prostaglandins', 'Joint swelling', 'Arthralgia', 'Rheumatoid arthritis']",Nabumetone,Rheumatoid arthritis,['(6-methoxy-2-naphthyl)acetic acid'],"['produces', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug Nabumetone via its mechanism of action in treating the Disease Rheumatoid arthritis ?,(6-methoxy-2-naphthyl)acetic acid
1157,DB04145_MESH_D010383_1,DRUGBANK:DB04145,MESH:D010383,"['MESH:D009540', 'HP:0100497', 'CHEBI:15940', 'MESH:D010383']",4,3,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - increases abundance of - ChemicalSubstance - negatively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:15940,MESH:D009540,"['Nicotinyl alcohol', 'Vitamin B3 deficiency', 'Nicotinic acid', 'Pellagra']",Nicotinyl alcohol,Pellagra,['Nicotinic acid'],"['increases abundance of', 'negatively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug Nicotinyl alcohol via its mechanism of action in treating the Disease Pellagra ?,Nicotinic acid
1159,DB04145_MESH_D006949_1,DRUGBANK:DB04145,MESH:D006949,"['MESH:D009540', 'CHEBI:15940', 'UniProt:P49019', 'UniProt:Q8TDS4', 'UniProt:Q96PD7', 'MESH:D005227', 'UniProt:P02656', 'MESH:D015243', 'MESH:D014280', 'MESH:D006949']",10,11,1,['Drug - ChemicalSubstance - Disease'],['Drug - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:15940,MESH:D009540,"['Nicotinyl alcohol', 'Nicotinic acid', 'Hydroxycarboxylic acid receptor 3', 'Hydroxycarboxylic acid receptor 2', 'Diacylglycerol O-acyltransferase 2', 'Fatty Acids', 'Apolipoprotein C-III', 'Cholesterol, VLDL', 'Triglycerides', 'Hyperlipidemia']",Nicotinyl alcohol,Hyperlipidemia,['Nicotinic acid'],"['increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug Nicotinyl alcohol via its mechanism of action in treating the Disease Hyperlipidemia ?,Nicotinic acid
1182,DB00484_MESH_D012393_1,DRUGBANK:DB00484,MESH:D012393,"['MESH:D000068438', 'UniProt:P08913', 'UniProt:P18089', 'UniProt:P18825', 'reactome:R-HSA-418594', 'reactome:R-HSA-418597', 'CHEBI:17489', 'GO:0042310', 'HP:0031284', 'HP:0001041', 'MESH:D012393']",11,16,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - increases activity of - Protein - participates in - Pathway - decreases abundance of - ChemicalSubstance - negatively correlated with - BiologicalProcess - negatively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:17489,MESH:D000068438,"['brimonidine', 'Alpha-2A adrenergic receptor', 'Alpha-2B adrenergic receptor', 'Alpha-2C adrenergic receptor', 'G alpha (i) signalling events', 'G alpha (z) signalling events', ""3',5'-cyclic AMP"", 'vasoconstriction', 'Flushing', 'Facial erythema', 'Rosacea']",brimonidine,Rosacea,"[""3',5'-cyclic AMP""]","['increases activity of', 'participates in', 'decreases abundance of', 'negatively correlated with', 'negatively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug brimonidine via its mechanism of action in treating the Disease Rosacea ?,"3',5'-cyclic AMP"
1191,DB01048_MESH_D015658_2,DRUGBANK:DB01048,MESH:D015658,"['MESH:C106538', 'CHEBI:64174', 'UniProt:Q72547', 'GO:0003964', 'GO:0019079', 'taxonomy:11676', 'MESH:D015658']",7,6,1,['Drug - ChemicalSubstance - Protein - MolecularActivity - BiologicalProcess - OrganismTaxon - Disease'],['Drug - produces - ChemicalSubstance - decreases activity of - Protein - positively regulates - MolecularActivity - positively correlated with - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:64174,MESH:C106538,"['abacavir', 'carbovir triphosphate', 'Reverse transcriptase/RNaseH', 'RNA-directed DNA polymerase activity', 'viral genome replication', 'Human immunodeficiency virus 1', 'Human immunodeficiency virus infection']",abacavir,Human immunodeficiency virus infection,['carbovir triphosphate'],"['produces', 'decreases activity of', 'positively regulates', 'positively correlated with', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug abacavir via its mechanism of action in treating the Disease Human immunodeficiency virus infection ?,carbovir triphosphate
1202,DB00484_MESH_D012393_2,DRUGBANK:DB00484,MESH:D012393,"['MESH:D000068438', 'MESH:D018341', 'reactome:R-HSA-418594', 'reactome:R-HSA-418597', 'CHEBI:17489', 'GO:0042310', 'HP:0031284', 'HP:0001041', 'MESH:D012393']",9,10,1,['Drug - GeneFamily - Pathway - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - increases activity of - GeneFamily - participates in - Pathway - decreases abundance of - ChemicalSubstance - negatively correlated with - BiologicalProcess - negatively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:17489,MESH:D000068438,"['brimonidine', 'Receptors, Adrenergic, alpha-2', 'G alpha (i) signalling events', 'G alpha (z) signalling events', ""3',5'-cyclic AMP"", 'vasoconstriction', 'Flushing', 'Facial erythema', 'Rosacea']",brimonidine,Rosacea,"[""3',5'-cyclic AMP""]","['increases activity of', 'participates in', 'decreases abundance of', 'negatively correlated with', 'negatively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug brimonidine via its mechanism of action in treating the Disease Rosacea ?,"3',5'-cyclic AMP"
1204,DB00279_MESH_D009230_1,DRUGBANK:DB00279,MESH:D009230,"['MESH:D014284', 'UniProt:P10827', 'UniProt:P10828', 'GO:0002154', 'GO:0070460', 'CHEBI:18085', 'HP:0000969', 'MESH:D009230']",8,8,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - increases activity of - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:18085,MESH:D014284,"['Triiodothyronine', 'Thyroid hormone receptor alpha', 'Thyroid hormone receptor beta', 'Thyroid hormone mediated signaling pathway', 'Thyroid-stimulating hormone secretion', 'Glycosaminoglycan', 'Edema', 'Myxedema']",Triiodothyronine,Myxedema,['Glycosaminoglycan'],"['increases activity of', 'positively regulates', 'increases abundance of', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug Triiodothyronine via its mechanism of action in treating the Disease Myxedema ?,Glycosaminoglycan
1227,DB00477_MESH_D011618_1,DRUGBANK:DB00477,MESH:D011618,"['MESH:D002746', 'UniProt:P14416', 'CHEBI:18243', 'GO:0032225', 'UBERON:0001017', 'HP:0008760', 'MESH:D011618']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively correlated with - ChemicalSubstance - correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - prevents - PhenotypicFeature - correlated with - Disease'],CHEBI:18243,MESH:D002746,"['chlorpromazine', 'D(2) dopamine receptor', 'Dopamine', 'regulation of synaptic transmission, dopaminergic', 'central nervous system', 'Violent behavior', 'Psychotic Disorders']",chlorpromazine,Psychotic Disorders,['Dopamine'],"['decreases activity of', 'positively correlated with', 'correlated with', 'located in', 'prevents', 'correlated with']",Which biochemical entity is affected by the Drug chlorpromazine via its mechanism of action in treating the Disease Psychotic Disorders ?,Dopamine
1228,DB00477_MESH_D017118_1,DRUGBANK:DB00477,MESH:D017118,"['MESH:D002746', 'UniProt:P14416', 'CHEBI:18243', 'GO:0032225', 'UBERON:0001017', 'HP:0033400', 'MESH:D017118']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively correlated with - ChemicalSubstance - correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - prevents - PhenotypicFeature - correlated with - Disease'],CHEBI:18243,MESH:D002746,"['chlorpromazine', 'D(2) dopamine receptor', 'Dopamine', 'regulation of synaptic transmission, dopaminergic', 'central nervous system', 'Acute abdomen', 'Porphyria, Acute Intermittent']",chlorpromazine,"Porphyria, Acute Intermittent",['Dopamine'],"['decreases activity of', 'positively correlated with', 'correlated with', 'located in', 'prevents', 'correlated with']","Which biochemical entity is affected by the Drug chlorpromazine via its mechanism of action in treating the Disease Porphyria, Acute Intermittent ?",Dopamine
1229,DB00477_MESH_D012559_1,DRUGBANK:DB00477,MESH:D012559,"['MESH:D002746', 'UniProt:P14416', 'CHEBI:18243', 'GO:0032225', 'UBERON:0001017', 'HP:0008760', 'MESH:D012559']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively correlated with - ChemicalSubstance - correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - prevents - PhenotypicFeature - correlated with - Disease'],CHEBI:18243,MESH:D002746,"['chlorpromazine', 'D(2) dopamine receptor', 'Dopamine', 'regulation of synaptic transmission, dopaminergic', 'central nervous system', 'Violent behavior', 'Schizophrenia']",chlorpromazine,Schizophrenia,['Dopamine'],"['decreases activity of', 'positively correlated with', 'correlated with', 'located in', 'prevents', 'correlated with']",Which biochemical entity is affected by the Drug chlorpromazine via its mechanism of action in treating the Disease Schizophrenia ?,Dopamine
1230,DB00477_MESH_D019958_1,DRUGBANK:DB00477,MESH:D019958,"['MESH:D002746', 'UniProt:P14416', 'CHEBI:18243', 'GO:0032225', 'UBERON:0001017', 'HP:0008760', 'MESH:D019958']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively correlated with - ChemicalSubstance - correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - prevents - PhenotypicFeature - correlated with - Disease'],CHEBI:18243,MESH:D002746,"['chlorpromazine', 'D(2) dopamine receptor', 'Dopamine', 'regulation of synaptic transmission, dopaminergic', 'central nervous system', 'Violent behavior', 'Attention Deficit and Disruptive Behavior Disorders']",chlorpromazine,Attention Deficit and Disruptive Behavior Disorders,['Dopamine'],"['decreases activity of', 'positively correlated with', 'correlated with', 'located in', 'prevents', 'correlated with']",Which biochemical entity is affected by the Drug chlorpromazine via its mechanism of action in treating the Disease Attention Deficit and Disruptive Behavior Disorders ?,Dopamine
1241,DB06663_MESH_D000308_1,DRUGBANK:DB06663,MESH:D000308,"['MESH:C517782', 'UniProt:P30872', 'UniProt:P30874', 'UniProt:P32745', 'UniProt:P35346', 'GO:0051460', 'GO:0051463', 'CHEBI:17650', 'MESH:D000308']",9,11,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - increases activity of - Protein - participates in - BiologicalProcess - decreases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:17650,MESH:C517782,"['pasireotide', 'Somatostatin receptor type 1', 'Somatostatin receptor type 2', 'Somatostatin receptor type 3', 'Somatostatin receptor type 5', 'negative regulation of corticotropin secretion', 'negative regulation of cortisol secretion', 'cortisol', 'Adrenocortical Hyperfunction']",pasireotide,Adrenocortical Hyperfunction,['cortisol'],"['increases activity of', 'participates in', 'decreases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug pasireotide via its mechanism of action in treating the Disease Adrenocortical Hyperfunction ?,cortisol
1335,DB01224_MESH_D012559_1,DRUGBANK:DB01224,MESH:D012559,"['MESH:D000069348', 'UniProt:P28223', 'UniProt:P14416', 'GO:0014046', 'CHEBI:18243', 'UBERON:0009834', 'UBERON:0001910', 'HP:0100543', 'HP:0030213', 'HP:0012154', 'HP:0002465', 'HP:0000741', 'HP:0000709', 'MESH:D012559']",14,19,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - located in - GrossAnatomicalStructure - correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:18243,MESH:D000069348,"['quetiapine', '5-hydroxytryptamine receptor 2A', 'D(2) dopamine receptor', 'dopamine secretion', 'Dopamine', 'dorsolateral prefrontal cortex', 'medial forebrain bundle', 'Cognitive impairment', 'Emotional blunting', 'Anhedonia', 'Poor speech', 'Apathy', 'Psychosis', 'Schizophrenia']",quetiapine,Schizophrenia,['Dopamine'],"['decreases activity of', 'positively regulates', 'increases abundance of', 'located in', 'correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug quetiapine via its mechanism of action in treating the Disease Schizophrenia ?,Dopamine
1438,DB01319_MESH_D015658_1,DRUGBANK:DB01319,MESH:D015658,"['MESH:C426859', 'CHEBI:40050', 'UniProt:Q72874', 'UniProt:P04591', 'GO:0019068', 'taxonomy:11676', 'MESH:D015658']",7,6,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - OrganismTaxon - Disease'],['Drug - increases abundance of - ChemicalSubstance - decreases activity of - Protein - participates in - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:40050,MESH:C426859,"['fosamprenavir', 'amprenavir', 'Protease', 'Gag polyprotein', 'virion assembly', 'Human immunodeficiency virus 1', 'Human immunodeficiency virus infection']",fosamprenavir,Human immunodeficiency virus infection,['amprenavir'],"['increases abundance of', 'decreases activity of', 'participates in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug fosamprenavir via its mechanism of action in treating the Disease Human immunodeficiency virus infection ?,amprenavir
1449,DB12625_MESH_D003924_1,DRUGBANK:DB12625,MESH:D003924,"['MESH:C557982', 'UniProt:P27487', 'CHEBI:80270', 'GO:0030073', 'GO:0070091', 'HP:0003074', 'MESH:D003924']",7,7,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - negatively regulates - Protein - negatively regulates - ChemicalSubstance - negatively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:80270,MESH:C557982,"['evogliptin', 'Dipeptidyl peptidase 4', 'Glucagon-like peptide 1', 'insulin secretion', 'glucagon secretion', 'Hyperglycemia', 'Diabetes Mellitus, Type 2']",evogliptin,"Diabetes Mellitus, Type 2",['Glucagon-like peptide 1'],"['negatively regulates', 'negatively regulates', 'negatively regulates', 'positively correlated with', 'positively correlated with']","Which biochemical entity is affected by the Drug evogliptin via its mechanism of action in treating the Disease Diabetes Mellitus, Type 2 ?",Glucagon-like peptide 1
1475,DB00451_MESH_D009230_1,DRUGBANK:DB00451,MESH:D009230,"['MESH:D013974', 'MESH:D014284', 'UniProt:P10827', 'UniProt:P10828', 'GO:0002154', 'GO:0070460', 'CHEBI:18085', 'HP:0000969', 'MESH:D009230']",9,9,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:18085,MESH:D013974,"['Levothyroxine', 'Triiodothyronine', 'Thyroid hormone receptor alpha', 'Thyroid hormone receptor beta', 'Thyroid hormone mediated signaling pathway', 'Thyroid-stimulating hormone secretion', 'Glycosaminoglycan', 'Edema', 'Myxedema']",Levothyroxine,Myxedema,['Glycosaminoglycan'],"['has metabolite', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug Levothyroxine via its mechanism of action in treating the Disease Myxedema ?,Glycosaminoglycan
1508,DB00061_MESH_C531816_1,DRUGBANK:DB00061,MESH:C531816,"['MESH:C051409', 'CHEBI:17256', 'CL:0000084', 'GO:0002456', 'MESH:C531816']",5,4,1,['Drug - ChemicalSubstance - Cell - BiologicalProcess - Disease'],['Drug - decreases abundance of - ChemicalSubstance - disrupts - Cell - positively correlated with - BiologicalProcess - negatively correlated with - Disease'],CHEBI:17256,MESH:C051409,"['Pegademase', ""2'-deoxyadenosine"", 'T cell', 'T cell mediated immunity', 'Adenosine deaminase deficiency']",Pegademase,Adenosine deaminase deficiency,"[""2'-deoxyadenosine""]","['decreases abundance of', 'disrupts', 'positively correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug Pegademase via its mechanism of action in treating the Disease Adenosine deaminase deficiency ?,2'-deoxyadenosine
1528,DB01152_MESH_D002181_1,DRUGBANK:DB01152,MESH:D002181,"['MESH:D002174', 'CHEBI:16933', 'GO:0030445', 'taxonomy:237561', 'MESH:D002181']",5,4,1,['Drug - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - negatively regulates - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:D002174,"['Candicidin', 'ergosterol', 'yeast-form cell wall', 'Candida albicans SC5314', 'Candidiasis, Vulvovaginal']",Candicidin,"Candidiasis, Vulvovaginal",['ergosterol'],"['negatively regulates', 'located in', 'in taxon', 'causes']","Which biochemical entity is affected by the Drug Candicidin via its mechanism of action in treating the Disease Candidiasis, Vulvovaginal ?",ergosterol
1571,DB00195_MESH_D009798_1,DRUGBANK:DB00195,MESH:D009798,"['MESH:D015784', 'UniProt:P08588', 'reactome:R-HSA-418555', 'CHEBI:17489', 'UBERON:0001796', 'MESH:D009798']",6,5,1,['Drug - Protein - Pathway - ChemicalSubstance - GrossAnatomicalStructure - Disease'],['Drug - decreases activity of - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - GrossAnatomicalStructure - positively correlated with - Disease'],CHEBI:17489,MESH:D015784,"['betaxolol', 'Beta-1 adrenergic receptor', 'G alpha (s) signalling events', ""3',5'-cyclic AMP"", 'aqueous humor of eyeball', 'Ocular hypertension']",betaxolol,Ocular hypertension,"[""3',5'-cyclic AMP""]","['decreases activity of', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug betaxolol via its mechanism of action in treating the Disease Ocular hypertension ?,"3',5'-cyclic AMP"
1572,DB00195_MESH_D005902_1,DRUGBANK:DB00195,MESH:D005902,"['MESH:D015784', 'UniProt:P08588', 'reactome:R-HSA-418555', 'CHEBI:17489', 'UBERON:0001796', 'HP:0007906', 'MESH:D005902']",7,6,1,['Drug - Protein - Pathway - ChemicalSubstance - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - GrossAnatomicalStructure - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:17489,MESH:D015784,"['betaxolol', 'Beta-1 adrenergic receptor', 'G alpha (s) signalling events', ""3',5'-cyclic AMP"", 'aqueous humor of eyeball', 'Ocular Hypertension', 'Open-angle glaucoma']",betaxolol,Open-angle glaucoma,"[""3',5'-cyclic AMP""]","['decreases activity of', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug betaxolol via its mechanism of action in treating the Disease Open-angle glaucoma ?,"3',5'-cyclic AMP"
1580,DB00322_MESH_D008113_1,DRUGBANK:DB00322,MESH:D008113,"['MESH:D005467', 'CHEBI:46345', 'UniProt:P04818', 'GO:0006235', 'GO:0006231', 'GO:0006260', 'HP:0031377', 'MESH:D008113']",8,8,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - Protein - positively regulates - BiologicalProcess - precedes - PhenotypicFeature - positively correlated with - Disease'],CHEBI:46345,MESH:D005467,"['floxuridine', '5-fluorouracil', 'Thymidylate synthase', 'dTTP biosynthetic process', 'dTMP biosynthetic process', 'Bacterial DNA replication', 'Abnormal cell proliferation', 'Liver Neoplasms']",floxuridine,Liver Neoplasms,['5-fluorouracil'],"['has metabolite', 'decreases activity of', 'positively regulates', 'precedes', 'positively correlated with']",Which biochemical entity is affected by the Drug floxuridine via its mechanism of action in treating the Disease Liver Neoplasms ?,5-fluorouracil
1585,DB00424_MESH_D053159_1,DRUGBANK:DB00424,MESH:D053159,"['MESH:D064692', 'UniProt:P20309', 'CHEBI:15355', 'UBERON:0000381', 'GO:0060073', 'MESH:D053159']",6,5,1,['Drug - Protein - ChemicalSubstance - GrossAnatomicalStructure - BiologicalProcess - Disease'],['Drug - decreases activity of - Protein - positively correlated with - ChemicalSubstance - positively regulates - GrossAnatomicalStructure - positively regulates - BiologicalProcess - manifestation of - Disease'],CHEBI:15355,MESH:D064692,"['Hyoscyamine', 'Muscarinic acetylcholine receptor M3', 'acetylcholine', 'Urinary bladder detrusor smooth muscle', 'Micturition', 'Dysuria']",Hyoscyamine,Dysuria,['acetylcholine'],"['decreases activity of', 'positively correlated with', 'positively regulates', 'positively regulates', 'manifestation of']",Which biochemical entity is affected by the Drug Hyoscyamine via its mechanism of action in treating the Disease Dysuria ?,acetylcholine
1677,DB00822_MESH_D000437_1,DRUGBANK:DB00822,MESH:D000437,"['MESH:D004221', 'UniProt:P05091', 'CHEBI:15343', 'GO:0006069', 'HP:0001033', 'HP:0002098', 'HP:0002017', 'MESH:D000437']",8,9,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - decreases abundance of - ChemicalSubstance - positively correlated with - PhenotypicFeature - negatively correlated with - Disease'],CHEBI:15343,MESH:D004221,"['disulfiram', 'Aldehyde dehydrogenase, mitochondrial', 'acetaldehyde', 'ethanol oxidation', 'Facial flushing after alcohol intake', 'Respiratory distress', 'Nausea and vomiting', 'Alcoholism']",disulfiram,Alcoholism,['acetaldehyde'],"['negatively regulates', 'positively regulates', 'decreases abundance of', 'positively correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug disulfiram via its mechanism of action in treating the Disease Alcoholism ?,acetaldehyde
1680,DB00239_MESH_D014010_1,DRUGBANK:DB00239,MESH:D014010,"['MESH:C022155', 'UniProt:P10613', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'taxonomy:237561', 'MESH:D014010']",7,6,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - produces - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:C022155,"['oxiconazole', 'Lanosterol 14-alpha-demethylase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Candida albicans SC5314', 'Tinea Versicolor']",oxiconazole,Tinea Versicolor,['ergosterol'],"['negatively regulates', 'positively regulates', 'produces', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug oxiconazole via its mechanism of action in treating the Disease Tinea Versicolor ?,ergosterol
1681,DB00239_MESH_D014008_1,DRUGBANK:DB00239,MESH:D014008,"['MESH:C022155', 'UniProt:P10613', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'taxonomy:237561', 'MESH:D014008']",7,6,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - produces - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:C022155,"['oxiconazole', 'Lanosterol 14-alpha-demethylase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Candida albicans SC5314', 'Tinea Pedis']",oxiconazole,Tinea Pedis,['ergosterol'],"['negatively regulates', 'positively regulates', 'produces', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug oxiconazole via its mechanism of action in treating the Disease Tinea Pedis ?,ergosterol
1701,DB06016_MESH_D012559_1,DRUGBANK:DB06016,MESH:D012559,"['MESH:C533287', 'UniProt:P35462', 'UniProt:P14416', 'reactome:R-HSA-390651', 'GO:0014046', 'CHEBI:18243', 'MESH:D012559']",7,7,1,['Drug - Protein - Pathway - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:18243,MESH:C533287,"['cariprazine', 'D(3) dopamine receptor', 'D(2) dopamine receptor', 'Dopamine receptor', 'dopamine secretion', 'Dopamine', 'Schizophrenia']",cariprazine,Schizophrenia,['Dopamine'],"['negatively regulates', 'participates in', 'positively regulates', 'increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug cariprazine via its mechanism of action in treating the Disease Schizophrenia ?,Dopamine
1783,DB09351_MESH_D005902_1,DRUGBANK:DB09351,MESH:D005902,"['DB:DB09351', 'UniProt:P08588', 'reactome:R-HSA-418555', 'CHEBI:17489', 'UBERON:0001796', 'HP:0007906', 'MESH:D005902']",7,6,1,['Drug - Protein - Pathway - ChemicalSubstance - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - GrossAnatomicalStructure - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:17489,DRUGBANK:DB09351,"['Levobetaxolol', 'Beta-1 adrenergic receptor', 'G alpha (s) signalling events', ""3',5'-cyclic AMP"", 'aqueous humor of eyeball', 'Ocular Hypertension', 'Open-angle glaucoma']",Levobetaxolol,Open-angle glaucoma,"[""3',5'-cyclic AMP""]","['decreases activity of', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug Levobetaxolol via its mechanism of action in treating the Disease Open-angle glaucoma ?,"3',5'-cyclic AMP"
1784,DB09351_MESH_D009798_1,DRUGBANK:DB09351,MESH:D009798,"['DB:DB09351', 'UniProt:P08588', 'reactome:R-HSA-418555', 'CHEBI:17489', 'UBERON:0001796', 'MESH:D009798']",6,5,1,['Drug - Protein - Pathway - ChemicalSubstance - GrossAnatomicalStructure - Disease'],['Drug - decreases activity of - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - GrossAnatomicalStructure - positively correlated with - Disease'],CHEBI:17489,DRUGBANK:DB09351,"['Levobetaxolol', 'Beta-1 adrenergic receptor', 'G alpha (s) signalling events', ""3',5'-cyclic AMP"", 'aqueous humor of eyeball', 'Ocular hypertension']",Levobetaxolol,Ocular hypertension,"[""3',5'-cyclic AMP""]","['decreases activity of', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug Levobetaxolol via its mechanism of action in treating the Disease Ocular hypertension ?,"3',5'-cyclic AMP"
1812,DB00973_MESH_C537345_1,DRUGBANK:DB00973,MESH:C537345,"['MESH:D000069438', 'UniProt:Q9UHC9', 'GO:0098856', 'CHEBI:26125', 'HP:0033341', 'MESH:C537345']",6,5,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:26125,MESH:D000069438,"['ezetimibe', 'NPC1-like intracellular cholesterol transporter 1', 'intestinal lipid absorption', 'phytosterols', 'Elevated circulating sitosterol concentration', 'Sitosterolemia']",ezetimibe,Sitosterolemia,['phytosterols'],"['negatively regulates', 'positively regulates', 'increases abundance of', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug ezetimibe via its mechanism of action in treating the Disease Sitosterolemia ?,phytosterols
1813,DB00973_MESH_D006949_1,DRUGBANK:DB00973,MESH:D006949,"['MESH:D000069438', 'UniProt:Q9UHC9', 'GO:0098856', 'CHEBI:18059', 'MESH:D006949']",5,4,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:18059,MESH:D000069438,"['ezetimibe', 'NPC1-like intracellular cholesterol transporter 1', 'intestinal lipid absorption', 'lipid', 'Hyperlipidemia']",ezetimibe,Hyperlipidemia,['lipid'],"['negatively regulates', 'positively regulates', 'increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug ezetimibe via its mechanism of action in treating the Disease Hyperlipidemia ?,lipid
1815,DB00973_MESH_D006937_1,DRUGBANK:DB00973,MESH:D006937,"['MESH:D000069438', 'UniProt:Q9UHC9', 'GO:0098856', 'CHEBI:16113', 'MESH:D006937']",5,4,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:16113,MESH:D000069438,"['ezetimibe', 'NPC1-like intracellular cholesterol transporter 1', 'intestinal lipid absorption', 'cholesterol', 'Hypercholesterolemia']",ezetimibe,Hypercholesterolemia,['cholesterol'],"['negatively regulates', 'positively regulates', 'increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug ezetimibe via its mechanism of action in treating the Disease Hypercholesterolemia ?,cholesterol
1822,DB00853_MESH_D001254_1,DRUGBANK:DB00853,MESH:D001254,"['MESH:C047246', 'CHEBI:16991', 'GO:0014009', 'MESH:D001254']",4,3,1,['Drug - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - disrupts - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:16991,MESH:C047246,"['temozolomide', 'deoxyribonucleic acid', 'glial cell proliferation', 'Astrocytoma, anaplastic']",temozolomide,"Astrocytoma, anaplastic",['deoxyribonucleic acid'],"['disrupts', 'positively correlated with', 'positively correlated with']","Which biochemical entity is affected by the Drug temozolomide via its mechanism of action in treating the Disease Astrocytoma, anaplastic ?",deoxyribonucleic acid
1901,DB00391_MESH_D012559_1,DRUGBANK:DB00391,MESH:D012559,"['MESH:D013469', 'UniProt:P14416', 'UniProt:P35462', 'reactome:R-HSA-390651', 'GO:0014046', 'CHEBI:18243', 'MESH:D012559']",7,7,1,['Drug - Protein - Pathway - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:18243,MESH:D013469,"['sulpiride', 'D(2) dopamine receptor', 'D(3) dopamine receptor', 'Dopamine receptor', 'dopamine secretion', 'Dopamine', 'Schizophrenia']",sulpiride,Schizophrenia,['Dopamine'],"['negatively regulates', 'participates in', 'positively regulates', 'increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug sulpiride via its mechanism of action in treating the Disease Schizophrenia ?,Dopamine
1936,DB08868_MESH_D020529_1,DRUGBANK:DB08868,MESH:D020529,"['MESH:D000068876', 'CHEBI:73420', 'UniProt:Q99500', 'UniProt:Q9H228', 'UniProt:P21453', 'GO:0072676', 'GO:0006954', 'MESH:D020529']",8,9,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - negatively regulates - BiologicalProcess - positively correlated with - Disease'],CHEBI:73420,MESH:D000068876,"['Fingolimod', 'Fingolimod phosphate', 'Sphingosine 1-phosphate receptor 3', 'Sphingosine 1-phosphate receptor 5', 'Sphingosine 1-phosphate receptor 1', 'Lymphocyte migration', 'inflammatory response', 'Relapsing remitting multiple sclerosis']",Fingolimod,Relapsing remitting multiple sclerosis,['Fingolimod phosphate'],"['has metabolite', 'increases activity of', 'negatively regulates', 'positively correlated with']",Which biochemical entity is affected by the Drug Fingolimod via its mechanism of action in treating the Disease Relapsing remitting multiple sclerosis ?,Fingolimod phosphate
1963,DB03808_MESH_D015823_1,DRUGBANK:DB03808,MESH:D015823,"['MESH:C018961', 'CHEBI:18059', 'GO:0016020', 'taxonomy:5754', 'MESH:D015823']",5,4,1,['Drug - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - molecularly interacts with - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:18059,MESH:C018961,"['hexamidine', 'lipid', 'membrane', 'Acanthamoeba sp.', 'Acanthamoeba keratitis']",hexamidine,Acanthamoeba keratitis,['lipid'],"['molecularly interacts with', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug hexamidine via its mechanism of action in treating the Disease Acanthamoeba keratitis ?,lipid
1992,DB09082_MESH_D029424_1,DRUGBANK:DB09082,MESH:D029424,"['MESH:C550468', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'UBERON:0002185', 'MESH:D029424']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - affected by - Disease'],CHEBI:17489,MESH:C550468,"['Vilanterol', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'bronchus', 'Chronic obstructive lung disease']",Vilanterol,Chronic obstructive lung disease,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'positively correlated with', 'located in', 'affected by']",Which biochemical entity is affected by the Drug Vilanterol via its mechanism of action in treating the Disease Chronic obstructive lung disease ?,"3',5'-cyclic AMP"
1993,DB09082_MESH_D011656_1,DRUGBANK:DB09082,MESH:D011656,"['MESH:C550468', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'UBERON:0002185', 'UBERON:0002048', 'MESH:D011656']",8,7,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - affected by - Disease'],CHEBI:17489,MESH:C550468,"['Vilanterol', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'bronchus', 'lung', 'Pulmonary emphysema']",Vilanterol,Pulmonary emphysema,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'positively correlated with', 'located in', 'affected by']",Which biochemical entity is affected by the Drug Vilanterol via its mechanism of action in treating the Disease Pulmonary emphysema ?,"3',5'-cyclic AMP"
1994,DB09082_MESH_D029481_1,DRUGBANK:DB09082,MESH:D029481,"['MESH:C550468', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'UBERON:0002185', 'MESH:D029481']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - affected by - Disease'],CHEBI:17489,MESH:C550468,"['Vilanterol', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'bronchus', 'Chronic bronchitis']",Vilanterol,Chronic bronchitis,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'positively correlated with', 'located in', 'affected by']",Which biochemical entity is affected by the Drug Vilanterol via its mechanism of action in treating the Disease Chronic bronchitis ?,"3',5'-cyclic AMP"
1995,DB09082_MESH_D001249_1,DRUGBANK:DB09082,MESH:D001249,"['MESH:C550468', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'UBERON:0002185', 'MESH:D001249']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - affected by - Disease'],CHEBI:17489,MESH:C550468,"['Vilanterol', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'bronchus', 'Asthma']",Vilanterol,Asthma,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'positively correlated with', 'located in', 'affected by']",Which biochemical entity is affected by the Drug Vilanterol via its mechanism of action in treating the Disease Asthma ?,"3',5'-cyclic AMP"
2039,DB09263_MESH_D006947_1,DRUGBANK:DB09263,MESH:D006947,"['MESH:C568789', 'CHEBI:29103', 'MESH:D006947']",3,2,1,['Drug - ChemicalSubstance - Disease'],['Drug - decreases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:29103,MESH:C568789,"['Patiromer calcium', 'Potassium(1+)', 'Hyperkalemia']",Patiromer calcium,Hyperkalemia,['Potassium(1+)'],"['decreases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug Patiromer calcium via its mechanism of action in treating the Disease Hyperkalemia ?,Potassium(1+)
2084,DB00862_MESH_D007172_1,DRUGBANK:DB00862,MESH:D007172,"['MESH:D000069058', 'UniProt:O76074', 'CHEBI:16356', 'GO:0044557', 'GO:0008015', 'GO:0043084', 'MESH:D007172']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - decreases activity of - Protein - decreases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:16356,MESH:D000069058,"['Vardenafil', ""cGMP-specific 3',5'-cyclic phosphodiesterase"", ""cyclic guanosine 3',5' monophosphate"", 'relaxation of smooth muscle', 'Blood circulation', 'Penile erection', 'Impotence']",Vardenafil,Impotence,"[""cyclic guanosine 3',5' monophosphate""]","['decreases activity of', 'decreases abundance of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug Vardenafil via its mechanism of action in treating the Disease Impotence ?,"cyclic guanosine 3',5' monophosphate"
2112,DB00857_MESH_D014008_1,DRUGBANK:DB00857,MESH:D014008,"['MESH:C041359', 'InterPro:IPR040125', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'taxonomy:5551', 'MESH:D014008']",7,6,1,['Drug - GeneFamily - BiologicalProcess - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - negatively regulates - GeneFamily - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:C041359,"['terbinafine', 'Squalene monooxygenase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Trichophyton rubrum', 'Tinea Pedis']",terbinafine,Tinea Pedis,['ergosterol'],"['negatively regulates', 'positively regulates', 'increases abundance of', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug terbinafine via its mechanism of action in treating the Disease Tinea Pedis ?,ergosterol
2113,DB00857_MESH_D014010_1,DRUGBANK:DB00857,MESH:D014010,"['MESH:C041359', 'InterPro:IPR040125', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'taxonomy:55194', 'MESH:D014010']",7,6,1,['Drug - GeneFamily - BiologicalProcess - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - negatively regulates - GeneFamily - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:C041359,"['terbinafine', 'Squalene monooxygenase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Malassezia furfur', 'Tinea Versicolor']",terbinafine,Tinea Versicolor,['ergosterol'],"['negatively regulates', 'positively regulates', 'increases abundance of', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug terbinafine via its mechanism of action in treating the Disease Tinea Versicolor ?,ergosterol
2114,DB00857_MESH_D014006_1,DRUGBANK:DB00857,MESH:D014006,"['MESH:C041359', 'InterPro:IPR040125', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'taxonomy:5550', 'MESH:D014006']",7,6,1,['Drug - GeneFamily - BiologicalProcess - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - negatively regulates - GeneFamily - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:C041359,"['terbinafine', 'Squalene monooxygenase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Trichophyton sp', 'Tinea capitis']",terbinafine,Tinea capitis,['ergosterol'],"['negatively regulates', 'positively regulates', 'increases abundance of', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug terbinafine via its mechanism of action in treating the Disease Tinea capitis ?,ergosterol
2115,DB00857_MESH_D014009_1,DRUGBANK:DB00857,MESH:D014009,"['MESH:C041359', 'InterPro:IPR040125', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'taxonomy:34384', 'MESH:D014009']",7,6,1,['Drug - GeneFamily - BiologicalProcess - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - negatively regulates - GeneFamily - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:C041359,"['terbinafine', 'Squalene monooxygenase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Arthrodermataceae', 'Onychomycosis due to dermatophyte']",terbinafine,Onychomycosis due to dermatophyte,['ergosterol'],"['negatively regulates', 'positively regulates', 'increases abundance of', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug terbinafine via its mechanism of action in treating the Disease Onychomycosis due to dermatophyte ?,ergosterol
2118,DB01611_MESH_D016778_1,DRUGBANK:DB01611,MESH:D016778,"['MESH:D006886', 'MESH:D006418', 'CHEBI:36161', 'taxonomy:5833', 'MESH:D016778']",5,5,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - molecularly interacts with - ChemicalSubstance - disrupts - OrganismTaxon - causes - Disease'],CHEBI:36161,MESH:D006886,"['hydroxychloroquine', 'Heme', 'hematin', 'Plasmodium falciparum', 'Falciparum malaria']",hydroxychloroquine,Falciparum malaria,['hematin'],"['molecularly interacts with', 'disrupts', 'causes']",Which biochemical entity is affected by the Drug hydroxychloroquine via its mechanism of action in treating the Disease Falciparum malaria ?,hematin
2121,DB01611_MESH_D016780_1,DRUGBANK:DB01611,MESH:D016780,"['MESH:D006886', 'MESH:D006418', 'CHEBI:36161', 'taxonomy:5855', 'MESH:D016780']",5,5,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - molecularly interacts with - ChemicalSubstance - disrupts - OrganismTaxon - causes - Disease'],CHEBI:36161,MESH:D006886,"['hydroxychloroquine', 'Heme', 'hematin', 'Plasmodium vivax', 'Vivax malaria']",hydroxychloroquine,Vivax malaria,['hematin'],"['molecularly interacts with', 'disrupts', 'causes']",Which biochemical entity is affected by the Drug hydroxychloroquine via its mechanism of action in treating the Disease Vivax malaria ?,hematin
2125,DB00974_MESH_D006934_1,DRUGBANK:DB00974,MESH:D006934,"['MESH:D004492', 'CHEBI:29108', 'UBERON:0001977', 'MESH:D006934']",4,3,1,['Drug - ChemicalSubstance - GrossAnatomicalStructure - Disease'],['Drug - decreases abundance of - ChemicalSubstance - located in - GrossAnatomicalStructure - location of - Disease'],CHEBI:29108,MESH:D004492,"['edetic acid', 'calcium(2+)', 'blood serum', 'Hypercalcemia']",edetic acid,Hypercalcemia,['calcium(2+)'],"['decreases abundance of', 'located in', 'location of']",Which biochemical entity is affected by the Drug edetic acid via its mechanism of action in treating the Disease Hypercalcemia ?,calcium(2+)
2166,DB00581_MESH_D006501_1,DRUGBANK:DB00581,MESH:D006501,"['MESH:D007792', 'CHEBI:16134', 'HP:0001987', 'MESH:D006501']",4,3,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - decreases abundance of - ChemicalSubstance - correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:16134,MESH:D007792,"['lactulose', 'ammonia', 'Hyperammonemia', 'Hepatic Encephalopathy']",lactulose,Hepatic Encephalopathy,['ammonia'],"['decreases abundance of', 'correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug lactulose via its mechanism of action in treating the Disease Hepatic Encephalopathy ?,ammonia
2167,DB00581_MESH_D022124_1,DRUGBANK:DB00581,MESH:D022124,"['MESH:D007792', 'CHEBI:16134', 'HP:0004364', 'MESH:D022124']",4,3,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - decreases abundance of - ChemicalSubstance - correlated with - PhenotypicFeature - superclass of - Disease'],CHEBI:16134,MESH:D007792,"['lactulose', 'ammonia', 'Abnormal circulating nitrogen compound concentration', 'Hyperammonemia']",lactulose,Hyperammonemia,['ammonia'],"['decreases abundance of', 'correlated with', 'superclass of']",Which biochemical entity is affected by the Drug lactulose via its mechanism of action in treating the Disease Hyperammonemia ?,ammonia
2190,DB01218_MESH_D016778_1,DRUGBANK:DB01218,MESH:D016778,"['MESH:C023768', 'CHEBI:15430', 'taxonomy:5833', 'MESH:D016778']",4,3,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - molecularly interacts with - ChemicalSubstance - disrupts - OrganismTaxon - causes - Disease'],CHEBI:15430,MESH:C023768,"['halofantrine', 'protoporphyrin', 'Plasmodium falciparum', 'Falciparum malaria']",halofantrine,Falciparum malaria,['protoporphyrin'],"['molecularly interacts with', 'disrupts', 'causes']",Which biochemical entity is affected by the Drug halofantrine via its mechanism of action in treating the Disease Falciparum malaria ?,protoporphyrin
2191,DB01218_MESH_D016780_1,DRUGBANK:DB01218,MESH:D016780,"['MESH:C023768', 'CHEBI:15430', 'taxonomy:5855', 'MESH:D016780']",4,3,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - molecularly interacts with - ChemicalSubstance - disrupts - OrganismTaxon - causes - Disease'],CHEBI:15430,MESH:C023768,"['halofantrine', 'protoporphyrin', 'Plasmodium vivax', 'Vivax malaria']",halofantrine,Vivax malaria,['protoporphyrin'],"['molecularly interacts with', 'disrupts', 'causes']",Which biochemical entity is affected by the Drug halofantrine via its mechanism of action in treating the Disease Vivax malaria ?,protoporphyrin
2238,DB09042_MESH_D017192_1,DRUGBANK:DB09042,MESH:D017192,"['MESH:C515040', 'CHEBI:82717', 'GO:0005840', 'GO:0006412', 'taxonomy:2', 'MESH:D017192']",6,5,1,['Drug - ChemicalSubstance - CellularComponent - BiologicalProcess - OrganismTaxon - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - CellularComponent - positively regulates - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:82717,MESH:C515040,"['Tedizolid phosphate', 'Tedizolid', 'ribosome', 'translation', 'Bacteria', 'Skin Diseases, Bacterial']",Tedizolid phosphate,"Skin Diseases, Bacterial",['Tedizolid'],"['has metabolite', 'decreases activity of', 'positively regulates', 'in taxon', 'causes']","Which biochemical entity is affected by the Drug Tedizolid phosphate via its mechanism of action in treating the Disease Skin Diseases, Bacterial ?",Tedizolid
2240,DB00090_MESH_D008059_2,DRUGBANK:DB00090,MESH:D008059,"['DB:DB00090', 'UniProt:P35475', 'CHEBI:43394', 'MESH:D006025', 'MESH:D008059']",5,4,1,['Drug - Protein - ChemicalSubstance - Disease'],['Drug - chemically similar to - Protein - increases degradation of - ChemicalSubstance - manifestation of - Disease'],CHEBI:43394,DRUGBANK:DB00090,"['laronidase', 'Alpha-L-iduronidase', 'α-L-iduronic acid', 'Glycosaminoglycan', 'Mucopolysaccharidosis, MPS-I']",laronidase,"Mucopolysaccharidosis, MPS-I",['α-L-iduronic acid'],"['chemically similar to', 'increases degradation of', 'manifestation of']","Which biochemical entity is affected by the Drug laronidase via its mechanism of action in treating the Disease Mucopolysaccharidosis, MPS-I ?",α-L-iduronic acid
2241,DB00137_MESH_D008268_2,DRUGBANK:DB00137,MESH:D008268,"['MESH:D014975', 'CHEBI:23044', 'UBERON:0000054', 'GO:0016209', 'MESH:D008268']",5,4,1,['Drug - ChemicalSubstance - GrossAnatomicalStructure - MolecularActivity - Disease'],['Drug - chemically similar to - ChemicalSubstance - located in - GrossAnatomicalStructure - participates in - MolecularActivity - prevents - Disease'],CHEBI:23044,MESH:D014975,"['lutein', 'carotenoid', 'Macula', 'antioxidant activity', 'Age related macular degeneration']",lutein,Age related macular degeneration,['carotenoid'],"['chemically similar to', 'located in', 'participates in', 'prevents']",Which biochemical entity is affected by the Drug lutein via its mechanism of action in treating the Disease Age related macular degeneration ?,carotenoid
2242,DB00137_MESH_D015352_2,DRUGBANK:DB00137,MESH:D015352,"['MESH:D014975', 'CHEBI:23044', 'UBERON:0000054', 'GO:0016209', 'MESH:D015352']",5,4,1,['Drug - ChemicalSubstance - GrossAnatomicalStructure - MolecularActivity - Disease'],['Drug - chemically similar to - ChemicalSubstance - located in - GrossAnatomicalStructure - participates in - MolecularActivity - prevents - Disease'],CHEBI:23044,MESH:D014975,"['lutein', 'carotenoid', 'Macula', 'antioxidant activity', 'Tear film insufficiency']",lutein,Tear film insufficiency,['carotenoid'],"['chemically similar to', 'located in', 'participates in', 'prevents']",Which biochemical entity is affected by the Drug lutein via its mechanism of action in treating the Disease Tear film insufficiency ?,carotenoid
2243,DB00137_MESH_D000080343_2,DRUGBANK:DB00137,MESH:D000080343,"['MESH:D014975', 'CHEBI:23044', 'UBERON:0000054', 'GO:0016209', 'MESH:D000080343']",5,4,1,['Drug - ChemicalSubstance - GrossAnatomicalStructure - MolecularActivity - Disease'],['Drug - chemically similar to - ChemicalSubstance - located in - GrossAnatomicalStructure - participates in - MolecularActivity - prevents - Disease'],CHEBI:23044,MESH:D014975,"['lutein', 'carotenoid', 'Macula', 'antioxidant activity', 'Meibomian gland dysfunction']",lutein,Meibomian gland dysfunction,['carotenoid'],"['chemically similar to', 'located in', 'participates in', 'prevents']",Which biochemical entity is affected by the Drug lutein via its mechanism of action in treating the Disease Meibomian gland dysfunction ?,carotenoid
2254,DB00859_MESH_D003555_2,DRUGBANK:DB00859,MESH:D003555,"['MESH:D010396', 'GO:0046911', 'CHEBI:17376', 'HP:0003131', 'MESH:D003555']",5,4,1,['Drug - MolecularActivity - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - capable of - MolecularActivity - decreases abundance of - ChemicalSubstance - causes - PhenotypicFeature - manifestation of - Disease'],CHEBI:17376,MESH:D010396,"['penicillamine', 'metal chelating activity', 'cystine', 'Cystinuria', 'Cystinuria']",penicillamine,Cystinuria,['cystine'],"['capable of', 'decreases abundance of', 'causes', 'manifestation of']",Which biochemical entity is affected by the Drug penicillamine via its mechanism of action in treating the Disease Cystinuria ?,cystine
2258,DB00394_MESH_D012220_1,DRUGBANK:DB00394,MESH:D012220,"['DB:DB00394', 'CHEBI:3001', 'UniProt:P04150', 'GO:0006954', 'MESH:D012220']",5,4,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - positively regulates - Protein - negatively regulates - BiologicalProcess - positively correlated with - Disease'],CHEBI:3001,DRUGBANK:DB00394,"['Beclomethasone dipropionate', 'beclomethasone', 'Glucocorticoid receptor', 'inflammatory response', 'Rhinitis']",Beclomethasone dipropionate,Rhinitis,['beclomethasone'],"['has metabolite', 'positively regulates', 'negatively regulates', 'positively correlated with']",Which biochemical entity is affected by the Drug Beclomethasone dipropionate via its mechanism of action in treating the Disease Rhinitis ?,beclomethasone
2259,DB00394_MESH_D012223_1,DRUGBANK:DB00394,MESH:D012223,"['DB:DB00394', 'CHEBI:3001', 'UniProt:P04150', 'GO:0042311', 'MESH:D012223']",5,4,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - positively regulates - Protein - negatively regulates - BiologicalProcess - positively correlated with - Disease'],CHEBI:3001,DRUGBANK:DB00394,"['Beclomethasone dipropionate', 'beclomethasone', 'Glucocorticoid receptor', 'vasodilation', 'Rhinitis, Vasomotor']",Beclomethasone dipropionate,"Rhinitis, Vasomotor",['beclomethasone'],"['has metabolite', 'positively regulates', 'negatively regulates', 'positively correlated with']","Which biochemical entity is affected by the Drug Beclomethasone dipropionate via its mechanism of action in treating the Disease Rhinitis, Vasomotor ?",beclomethasone
2260,DB00394_MESH_D009298_1,DRUGBANK:DB00394,MESH:D009298,"['DB:DB00394', 'CHEBI:3001', 'UniProt:P04150', 'GO:0006954', 'MESH:D009298']",5,4,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - positively regulates - Protein - negatively regulates - BiologicalProcess - positively correlated with - Disease'],CHEBI:3001,DRUGBANK:DB00394,"['Beclomethasone dipropionate', 'beclomethasone', 'Glucocorticoid receptor', 'inflammatory response', 'Nasal polyp']",Beclomethasone dipropionate,Nasal polyp,['beclomethasone'],"['has metabolite', 'positively regulates', 'negatively regulates', 'positively correlated with']",Which biochemical entity is affected by the Drug Beclomethasone dipropionate via its mechanism of action in treating the Disease Nasal polyp ?,beclomethasone
2261,DB00394_MESH_D001249_1,DRUGBANK:DB00394,MESH:D001249,"['DB:DB00394', 'CHEBI:3001', 'UniProt:P04150', 'GO:0006954', 'MESH:D001249']",5,4,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - positively regulates - Protein - negatively regulates - BiologicalProcess - positively correlated with - Disease'],CHEBI:3001,DRUGBANK:DB00394,"['Beclomethasone dipropionate', 'beclomethasone', 'Glucocorticoid receptor', 'inflammatory response', 'Asthma']",Beclomethasone dipropionate,Asthma,['beclomethasone'],"['has metabolite', 'positively regulates', 'negatively regulates', 'positively correlated with']",Which biochemical entity is affected by the Drug Beclomethasone dipropionate via its mechanism of action in treating the Disease Asthma ?,beclomethasone
2262,DB00394_MESH_D065631_1,DRUGBANK:DB00394,MESH:D065631,"['DB:DB00394', 'CHEBI:3001', 'UniProt:P04150', 'GO:0006954', 'MESH:D065631']",5,4,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - positively regulates - Protein - negatively regulates - BiologicalProcess - positively correlated with - Disease'],CHEBI:3001,DRUGBANK:DB00394,"['Beclomethasone dipropionate', 'beclomethasone', 'Glucocorticoid receptor', 'inflammatory response', 'Allergic rhinitis']",Beclomethasone dipropionate,Allergic rhinitis,['beclomethasone'],"['has metabolite', 'positively regulates', 'negatively regulates', 'positively correlated with']",Which biochemical entity is affected by the Drug Beclomethasone dipropionate via its mechanism of action in treating the Disease Allergic rhinitis ?,beclomethasone
2274,DB09517_MESH_D018798_1,DRUGBANK:DB09517,MESH:D018798,"['MESH:C011819', 'CHEBI:18248', 'GO:0055072', 'MESH:D018798']",4,3,1,['Drug - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - increases abundance of - ChemicalSubstance - correlated with - BiologicalProcess - negatively correlated with - Disease'],CHEBI:18248,MESH:C011819,"['ferrous gluconate', 'iron atom', 'iron ion homeostasis', 'Iron deficiency anemia']",ferrous gluconate,Iron deficiency anemia,['iron atom'],"['increases abundance of', 'correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug ferrous gluconate via its mechanism of action in treating the Disease Iron deficiency anemia ?,iron atom
2292,DB09043_MESH_D003924_1,DRUGBANK:DB09043,MESH:D003924,"['MESH:C534611', 'UniProt:P43220', 'CHEBI:80270', 'GO:0030073', 'GO:0070091', 'HP:0003074', 'MESH:D003924']",7,7,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - increases activity of - Protein - positively correlated with - ChemicalSubstance - negatively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:80270,MESH:C534611,"['Albiglutide', 'Glucagon-like peptide 1 receptor', 'Glucagon-like peptide 1', 'insulin secretion', 'glucagon secretion', 'Hyperglycemia', 'Diabetes Mellitus, Type 2']",Albiglutide,"Diabetes Mellitus, Type 2",['Glucagon-like peptide 1'],"['increases activity of', 'positively correlated with', 'negatively regulates', 'positively correlated with', 'manifestation of']","Which biochemical entity is affected by the Drug Albiglutide via its mechanism of action in treating the Disease Diabetes Mellitus, Type 2 ?",Glucagon-like peptide 1
2351,DB00525_MESH_D014006_1,DRUGBANK:DB00525,MESH:D014006,"['MESH:D014047', 'InterPro:IPR040125', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'taxonomy:5550', 'MESH:D014006']",7,6,1,['Drug - GeneFamily - BiologicalProcess - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - decreases activity of - GeneFamily - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:D014047,"['Tolnaftate', 'Squalene monooxygenase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Trichophyton sp', 'Tinea capitis']",Tolnaftate,Tinea capitis,['ergosterol'],"['decreases activity of', 'positively regulates', 'increases abundance of', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug Tolnaftate via its mechanism of action in treating the Disease Tinea capitis ?,ergosterol
2367,DB06219_MESH_D013207_1,DRUGBANK:DB06219,MESH:D013207,"['MESH:C469289', 'CHEBI:8005', 'GO:0009274', 'taxonomy:1280', 'MESH:D013207']",5,4,1,['Drug - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - disrupts - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:8005,MESH:C469289,"['dalbavancin', 'peptidoglycan', 'peptidoglycan-based cell wall', 'Staphylococcus aureus', 'Staphylococcal infection of skin']",dalbavancin,Staphylococcal infection of skin,['peptidoglycan'],"['disrupts', 'located in', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug dalbavancin via its mechanism of action in treating the Disease Staphylococcal infection of skin ?,peptidoglycan
2368,DB06219_MESH_D017192_1,DRUGBANK:DB06219,MESH:D017192,"['MESH:C469289', 'CHEBI:8005', 'GO:0009274', 'taxonomy:1280', 'MESH:D017192']",5,4,1,['Drug - ChemicalSubstance - CellularComponent - OrganismTaxon - Disease'],['Drug - disrupts - ChemicalSubstance - located in - CellularComponent - in taxon - OrganismTaxon - causes - Disease'],CHEBI:8005,MESH:C469289,"['dalbavancin', 'peptidoglycan', 'peptidoglycan-based cell wall', 'Staphylococcus aureus', 'Skin Diseases, Bacterial']",dalbavancin,"Skin Diseases, Bacterial",['peptidoglycan'],"['disrupts', 'located in', 'in taxon', 'causes']","Which biochemical entity is affected by the Drug dalbavancin via its mechanism of action in treating the Disease Skin Diseases, Bacterial ?",peptidoglycan
2369,DB00521_MESH_D005902_1,DRUGBANK:DB00521,MESH:D005902,"['MESH:D002354', 'UniProt:P08588', 'UniProt:P07550', 'reactome:R-HSA-418555', 'CHEBI:17489', 'UBERON:0001796', 'HP:0007906', 'MESH:D005902']",8,8,1,['Drug - Protein - Pathway - ChemicalSubstance - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - GrossAnatomicalStructure - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:17489,MESH:D002354,"['carteolol', 'Beta-1 adrenergic receptor', 'Beta-2 adrenergic receptor', 'G alpha (s) signalling events', ""3',5'-cyclic AMP"", 'aqueous humor of eyeball', 'Ocular Hypertension', 'Open-angle glaucoma']",carteolol,Open-angle glaucoma,"[""3',5'-cyclic AMP""]","['decreases activity of', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug carteolol via its mechanism of action in treating the Disease Open-angle glaucoma ?,"3',5'-cyclic AMP"
2371,DB00521_MESH_D009798_1,DRUGBANK:DB00521,MESH:D009798,"['MESH:D002354', 'UniProt:P08588', 'UniProt:P07550', 'reactome:R-HSA-418555', 'CHEBI:17489', 'UBERON:0001796', 'MESH:D009798']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - GrossAnatomicalStructure - Disease'],['Drug - decreases activity of - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - GrossAnatomicalStructure - positively correlated with - Disease'],CHEBI:17489,MESH:D002354,"['carteolol', 'Beta-1 adrenergic receptor', 'Beta-2 adrenergic receptor', 'G alpha (s) signalling events', ""3',5'-cyclic AMP"", 'aqueous humor of eyeball', 'Ocular hypertension']",carteolol,Ocular hypertension,"[""3',5'-cyclic AMP""]","['decreases activity of', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug carteolol via its mechanism of action in treating the Disease Ocular hypertension ?,"3',5'-cyclic AMP"
2372,DB00200_MESH_D014806_1,DRUGBANK:DB00200,MESH:D014806,"['MESH:D006879', 'CHEBI:30411', 'MESH:D014806']",3,2,1,['Drug - ChemicalSubstance - Disease'],['Drug - increases abundance of - ChemicalSubstance - negatively correlated with - Disease'],CHEBI:30411,MESH:D006879,"['hydroxocobalamin', 'cobalamin', 'Cobalamin deficiency']",hydroxocobalamin,Cobalamin deficiency,['cobalamin'],"['increases abundance of', 'negatively correlated with']",Which biochemical entity is affected by the Drug hydroxocobalamin via its mechanism of action in treating the Disease Cobalamin deficiency ?,cobalamin
2373,DB00200_MESH_D000752_1,DRUGBANK:DB00200,MESH:D000752,"['MESH:D006879', 'CHEBI:30411', 'HP:0001889', 'HP:0020060', 'MESH:D000752']",5,5,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - increases abundance of - ChemicalSubstance - negatively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:30411,MESH:D006879,"['hydroxocobalamin', 'cobalamin', 'Megaloblastic anemia', 'Decreased red blood cell count', 'Pernicious anemia']",hydroxocobalamin,Pernicious anemia,['cobalamin'],"['increases abundance of', 'negatively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug hydroxocobalamin via its mechanism of action in treating the Disease Pernicious anemia ?,cobalamin
2393,DB01096_MESH_D012552_1,DRUGBANK:DB01096,MESH:D012552,"['MESH:D010073', 'CHEBI:16991', 'taxonomy:6183', 'MESH:D012552']",4,3,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - disrupts - ChemicalSubstance - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16991,MESH:D010073,"['oxamniquine', 'deoxyribonucleic acid', 'Schistosoma mansoni', 'Infection by Schistosoma']",oxamniquine,Infection by Schistosoma,['deoxyribonucleic acid'],"['disrupts', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug oxamniquine via its mechanism of action in treating the Disease Infection by Schistosoma ?,deoxyribonucleic acid
2423,DB13132_MESH_D016778_1,DRUGBANK:DB13132,MESH:D016778,"['MESH:C031327', 'CHEBI:207229', 'UniProt:Q8I3Z5', 'taxonomy:5833', 'MESH:D016778']",5,4,1,['Drug - ChemicalSubstance - Protein - OrganismTaxon - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - Protein - part of - OrganismTaxon - causes - Disease'],CHEBI:207229,MESH:C031327,"['artemisinin', 'dihydroartemisinin', 'Translationally controlled tumor protein (TCTP) homolog', 'Plasmodium falciparum', 'Falciparum malaria']",artemisinin,Falciparum malaria,['dihydroartemisinin'],"['has metabolite', 'decreases activity of', 'part of', 'causes']",Which biochemical entity is affected by the Drug artemisinin via its mechanism of action in treating the Disease Falciparum malaria ?,dihydroartemisinin
2424,DB08872_MESH_D051474_2,DRUGBANK:DB08872,MESH:D051474,"['MESH:C493250', 'CHEBI:42797', 'UniProt:Q9NY47', 'GO:0098793', 'GO:0070509', 'GO:0007269', 'HP:0012531', 'MESH:D051474']",8,7,1,['Drug - ChemicalSubstance - Protein - CellularComponent - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - Protein - located in - CellularComponent - participates in - BiologicalProcess - participates in - PhenotypicFeature - correlated with - Disease'],CHEBI:42797,MESH:C493250,"['Gabapentin enacarbil', 'Gabapentin', 'Voltage-dependent calcium channel subunit alpha-2/delta-2', 'Presynapse', 'Calcium ion import', 'Neurotransmitter secretion', 'Pain', 'Postherpetic neuralgia']",Gabapentin enacarbil,Postherpetic neuralgia,['Gabapentin'],"['has metabolite', 'decreases activity of', 'located in', 'participates in', 'participates in', 'correlated with']",Which biochemical entity is affected by the Drug Gabapentin enacarbil via its mechanism of action in treating the Disease Postherpetic neuralgia ?,Gabapentin
2425,DB08872_MESH_D012148_2,DRUGBANK:DB08872,MESH:D012148,"['MESH:C493250', 'CHEBI:42797', 'UniProt:Q9NY47', 'GO:0098793', 'GO:0070509', 'GO:0007269', 'HP:0012514', 'MESH:D012148']",8,7,1,['Drug - ChemicalSubstance - Protein - CellularComponent - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - Protein - located in - CellularComponent - participates in - BiologicalProcess - participates in - PhenotypicFeature - correlated with - Disease'],CHEBI:42797,MESH:C493250,"['Gabapentin enacarbil', 'Gabapentin', 'Voltage-dependent calcium channel subunit alpha-2/delta-2', 'Presynapse', 'Calcium ion import', 'Neurotransmitter secretion', 'Lower limb pain', 'Restless legs']",Gabapentin enacarbil,Restless legs,['Gabapentin'],"['has metabolite', 'decreases activity of', 'located in', 'participates in', 'participates in', 'correlated with']",Which biochemical entity is affected by the Drug Gabapentin enacarbil via its mechanism of action in treating the Disease Restless legs ?,Gabapentin
2446,DB06267_MESH_D007172_1,DRUGBANK:DB06267,MESH:D007172,"['MESH:C419664', 'UniProt:O76074', 'CHEBI:16356', 'GO:0044557', 'GO:0008015', 'GO:0043084', 'MESH:D007172']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - decreases activity of - Protein - decreases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:16356,MESH:C419664,"['Udenafil', ""cGMP-specific 3',5'-cyclic phosphodiesterase"", ""cyclic guanosine 3',5' monophosphate"", 'relaxation of smooth muscle', 'Blood circulation', 'Penile erection', 'Impotence']",Udenafil,Impotence,"[""cyclic guanosine 3',5' monophosphate""]","['decreases activity of', 'decreases abundance of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug Udenafil via its mechanism of action in treating the Disease Impotence ?,"cyclic guanosine 3',5' monophosphate"
2465,DB00284_MESH_D003924_1,DRUGBANK:DB00284,MESH:D003924,"['MESH:D020909', 'UniProt:P04746', 'UniProt:O43451', 'GO:0016052', 'GO:0005983', 'CHEBI:17234', 'MESH:D003924']",7,7,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:17234,MESH:D020909,"['acarbose', 'Pancreatic alpha-amylase', 'Maltase-glucoamylase, intestinal', 'carbohydrate catabolic process', 'starch catabolic process', 'glucose', 'Diabetes Mellitus, Type 2']",acarbose,"Diabetes Mellitus, Type 2",['glucose'],"['negatively regulates', 'positively regulates', 'increases abundance of', 'positively correlated with']","Which biochemical entity is affected by the Drug acarbose via its mechanism of action in treating the Disease Diabetes Mellitus, Type 2 ?",glucose
2480,DB00816_MESH_D011656_1,DRUGBANK:DB00816,MESH:D011656,"['MESH:D009921', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'UBERON:0002187', 'MESH:D011656']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - location of - Disease'],CHEBI:17489,MESH:D009921,"['Orciprenaline', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'terminal bronchiole', 'Pulmonary emphysema']",Orciprenaline,Pulmonary emphysema,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'positively correlated with', 'located in', 'location of']",Which biochemical entity is affected by the Drug Orciprenaline via its mechanism of action in treating the Disease Pulmonary emphysema ?,"3',5'-cyclic AMP"
2533,DB01291_MESH_D011656_1,DRUGBANK:DB01291,MESH:D011656,"['MESH:C009118', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'UBERON:0002187', 'MESH:D011656']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - location of - Disease'],CHEBI:17489,MESH:C009118,"['Pirbuterol', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'terminal bronchiole', 'Pulmonary emphysema']",Pirbuterol,Pulmonary emphysema,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'positively correlated with', 'located in', 'location of']",Which biochemical entity is affected by the Drug Pirbuterol via its mechanism of action in treating the Disease Pulmonary emphysema ?,"3',5'-cyclic AMP"
2535,DB01291_MESH_D008171_1,DRUGBANK:DB01291,MESH:D008171,"['MESH:C009118', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'GO:0044557', 'UBERON:0002187', 'MESH:D008171']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - GrossAnatomicalStructure - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - located in - GrossAnatomicalStructure - affected by - Disease'],CHEBI:17489,MESH:C009118,"['Pirbuterol', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'relaxation of smooth muscle', 'terminal bronchiole', 'Disorder of lung']",Pirbuterol,Disorder of lung,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'positively correlated with', 'located in', 'affected by']",Which biochemical entity is affected by the Drug Pirbuterol via its mechanism of action in treating the Disease Disorder of lung ?,"3',5'-cyclic AMP"
2566,DB06590_MESH_D011018_1,DRUGBANK:DB06590,MESH:D011018,"['MESH:C515501', 'CHEBI:70729', 'InterPro:IPR001460', 'GO:0009252', 'GO:0009273', 'taxonomy:1313', 'MESH:D011018']",7,6,1,['Drug - ChemicalSubstance - GeneFamily - BiologicalProcess - OrganismTaxon - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - GeneFamily - positively regulates - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:70729,MESH:C515501,"['Ceftaroline fosamil', 'Ceftaroline', 'Penicillin-binding protein, transpeptidase', 'peptidoglycan biosynthetic process', 'peptidoglycan-based cell wall biogenesis', 'Streptococcus pneumoniae', 'Pneumonia due to Streptococcus']",Ceftaroline fosamil,Pneumonia due to Streptococcus,['Ceftaroline'],"['has metabolite', 'decreases activity of', 'positively regulates', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug Ceftaroline fosamil via its mechanism of action in treating the Disease Pneumonia due to Streptococcus ?,Ceftaroline
2567,DB06590_MESH_D013203_1,DRUGBANK:DB06590,MESH:D013203,"['MESH:C515501', 'CHEBI:70729', 'InterPro:IPR001460', 'GO:0018104', 'GO:0009273', 'GO:0005618', 'taxonomy:1280', 'MESH:D013203']",8,7,1,['Drug - ChemicalSubstance - GeneFamily - BiologicalProcess - CellularComponent - OrganismTaxon - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - GeneFamily - positively regulates - BiologicalProcess - has output - CellularComponent - occurs in - OrganismTaxon - causes - Disease'],CHEBI:70729,MESH:C515501,"['Ceftaroline fosamil', 'Ceftaroline', 'Penicillin-binding protein, transpeptidase', 'peptidoglycan-protein cross-linking', 'peptidoglycan-based cell wall biogenesis', 'Cell wall', 'Staphylococcus aureus', 'Staphylococcal Infections']",Ceftaroline fosamil,Staphylococcal Infections,['Ceftaroline'],"['has metabolite', 'decreases activity of', 'positively regulates', 'has output', 'occurs in', 'causes']",Which biochemical entity is affected by the Drug Ceftaroline fosamil via its mechanism of action in treating the Disease Staphylococcal Infections ?,Ceftaroline
2568,DB06590_MESH_D012226_1,DRUGBANK:DB06590,MESH:D012226,"['MESH:C515501', 'CHEBI:70729', 'InterPro:IPR001460', 'GO:0018104', 'GO:0009273', 'GO:0005618', 'taxonomy:39831', 'MESH:D012226']",8,7,1,['Drug - ChemicalSubstance - GeneFamily - BiologicalProcess - CellularComponent - OrganismTaxon - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - GeneFamily - positively regulates - BiologicalProcess - has output - CellularComponent - occurs in - OrganismTaxon - causes - Disease'],CHEBI:70729,MESH:C515501,"['Ceftaroline fosamil', 'Ceftaroline', 'Penicillin-binding protein, transpeptidase', 'peptidoglycan-protein cross-linking', 'peptidoglycan-based cell wall biogenesis', 'Cell wall', 'Klebsiella pneumoniae subsp. rhinoscleromatis', 'Rhinoscleroma']",Ceftaroline fosamil,Rhinoscleroma,['Ceftaroline'],"['has metabolite', 'decreases activity of', 'positively regulates', 'has output', 'occurs in', 'causes']",Which biochemical entity is affected by the Drug Ceftaroline fosamil via its mechanism of action in treating the Disease Rhinoscleroma ?,Ceftaroline
2569,DB06590_MESH_D004927_1,DRUGBANK:DB06590,MESH:D004927,"['MESH:C515501', 'CHEBI:70729', 'InterPro:IPR001460', 'GO:0018104', 'GO:0009273', 'GO:0005618', 'taxonomy:562', 'MESH:D004927']",8,7,1,['Drug - ChemicalSubstance - GeneFamily - BiologicalProcess - CellularComponent - OrganismTaxon - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - GeneFamily - positively regulates - BiologicalProcess - has output - CellularComponent - occurs in - OrganismTaxon - causes - Disease'],CHEBI:70729,MESH:C515501,"['Ceftaroline fosamil', 'Ceftaroline', 'Penicillin-binding protein, transpeptidase', 'peptidoglycan-protein cross-linking', 'peptidoglycan-based cell wall biogenesis', 'Cell wall', 'Escherichia coli', 'Escherichia coli Infections']",Ceftaroline fosamil,Escherichia coli Infections,['Ceftaroline'],"['has metabolite', 'decreases activity of', 'positively regulates', 'has output', 'occurs in', 'causes']",Which biochemical entity is affected by the Drug Ceftaroline fosamil via its mechanism of action in treating the Disease Escherichia coli Infections ?,Ceftaroline
2570,DB06590_MESH_D013290_1,DRUGBANK:DB06590,MESH:D013290,"['MESH:C515501', 'CHEBI:70729', 'InterPro:IPR001460', 'GO:0018104', 'GO:0009273', 'GO:0005618', 'taxonomy:1314', 'MESH:D013290']",8,7,1,['Drug - ChemicalSubstance - GeneFamily - BiologicalProcess - CellularComponent - OrganismTaxon - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - GeneFamily - positively regulates - BiologicalProcess - has output - CellularComponent - occurs in - OrganismTaxon - causes - Disease'],CHEBI:70729,MESH:C515501,"['Ceftaroline fosamil', 'Ceftaroline', 'Penicillin-binding protein, transpeptidase', 'peptidoglycan-protein cross-linking', 'peptidoglycan-based cell wall biogenesis', 'Cell wall', 'Streptococcus pyogenes', 'Streptococcal Infections']",Ceftaroline fosamil,Streptococcal Infections,['Ceftaroline'],"['has metabolite', 'decreases activity of', 'positively regulates', 'has output', 'occurs in', 'causes']",Which biochemical entity is affected by the Drug Ceftaroline fosamil via its mechanism of action in treating the Disease Streptococcal Infections ?,Ceftaroline
2664,DB09146_MESH_D054559_1,DRUGBANK:DB09146,MESH:D054559,"['MESH:C000599459', 'CHEBI:18367', 'MESH:D054559']",3,2,1,['Drug - ChemicalSubstance - Disease'],['Drug - decreases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:18367,MESH:C000599459,"['sucroferric oxyhydroxide', 'phosphate(3−)', 'Hyperphosphatemia']",sucroferric oxyhydroxide,Hyperphosphatemia,['phosphate(3−)'],"['decreases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug sucroferric oxyhydroxide via its mechanism of action in treating the Disease Hyperphosphatemia ?,phosphate(3−)
2701,DB04876_MESH_D003924_1,DRUGBANK:DB04876,MESH:D003924,"['MESH:C502012', 'UniProt:P27487', 'CHEBI:80270', 'GO:0030073', 'GO:0070091', 'HP:0003074', 'MESH:D003924']",7,7,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - negatively regulates - Protein - negatively regulates - ChemicalSubstance - negatively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:80270,MESH:C502012,"['Evogliptin', 'Dipeptidyl peptidase 4', 'Glucagon-like peptide 1', 'insulin secretion', 'glucagon secretion', 'Hyperglycemia', 'Diabetes Mellitus, Type 2']",Evogliptin,"Diabetes Mellitus, Type 2",['Glucagon-like peptide 1'],"['negatively regulates', 'negatively regulates', 'negatively regulates', 'positively correlated with', 'positively correlated with']","Which biochemical entity is affected by the Drug Evogliptin via its mechanism of action in treating the Disease Diabetes Mellitus, Type 2 ?",Glucagon-like peptide 1
2752,DB00328_MESH_D013717_1,DRUGBANK:DB00328,MESH:D013717,"['MESH:D007213', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0006954', 'MESH:D013717']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:26333,MESH:D007213,"['indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'inflammatory response', 'Tenosynovitis']",indomethacin,Tenosynovitis,['prostaglandin'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug indomethacin via its mechanism of action in treating the Disease Tenosynovitis ?,prostaglandin
2753,DB00328_MESH_D002062_1,DRUGBANK:DB00328,MESH:D002062,"['MESH:D007213', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0006954', 'MESH:D002062']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:26333,MESH:D007213,"['indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'inflammatory response', 'Bursitis']",indomethacin,Bursitis,['prostaglandin'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug indomethacin via its mechanism of action in treating the Disease Bursitis ?,prostaglandin
2754,DB00328_MESH_D001172_1,DRUGBANK:DB00328,MESH:D001172,"['MESH:D007213', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0006954', 'MESH:D001172']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:26333,MESH:D007213,"['indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'inflammatory response', 'Rheumatoid arthritis']",indomethacin,Rheumatoid arthritis,['prostaglandin'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug indomethacin via its mechanism of action in treating the Disease Rheumatoid arthritis ?,prostaglandin
2755,DB00328_MESH_D013167_1,DRUGBANK:DB00328,MESH:D013167,"['MESH:D007213', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0006954', 'MESH:D013167']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:26333,MESH:D007213,"['indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'inflammatory response', 'Ankylosing spondylitis']",indomethacin,Ankylosing spondylitis,['prostaglandin'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug indomethacin via its mechanism of action in treating the Disease Ankylosing spondylitis ?,prostaglandin
2756,DB00328_MESH_D006073_1,DRUGBANK:DB00328,MESH:D006073,"['MESH:D007213', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0006954', 'MESH:D006073']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:26333,MESH:D007213,"['indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'inflammatory response', 'Gout']",indomethacin,Gout,['prostaglandin'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug indomethacin via its mechanism of action in treating the Disease Gout ?,prostaglandin
2757,DB00328_MESH_D052256_1,DRUGBANK:DB00328,MESH:D052256,"['MESH:D007213', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0006954', 'MESH:D052256']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:26333,MESH:D007213,"['indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'inflammatory response', 'Tendinopathy']",indomethacin,Tendinopathy,['prostaglandin'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug indomethacin via its mechanism of action in treating the Disease Tendinopathy ?,prostaglandin
2758,DB00328_MESH_D013585_1,DRUGBANK:DB00328,MESH:D013585,"['MESH:D007213', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0006954', 'MESH:D013585']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:26333,MESH:D007213,"['indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'inflammatory response', 'Synovitis']",indomethacin,Synovitis,['prostaglandin'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug indomethacin via its mechanism of action in treating the Disease Synovitis ?,prostaglandin
2759,DB00328_MESH_D010003_1,DRUGBANK:DB00328,MESH:D010003,"['MESH:D007213', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0006954', 'MESH:D010003']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:26333,MESH:D007213,"['indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'inflammatory response', 'Osteoarthritis']",indomethacin,Osteoarthritis,['prostaglandin'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug indomethacin via its mechanism of action in treating the Disease Osteoarthritis ?,prostaglandin
2760,DB00328_MESH_D004374_1,DRUGBANK:DB00328,MESH:D004374,"['MESH:D007213', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0097070', 'MESH:D004374']",7,7,1,['Drug - Protein - Pathway - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - negatively correlated with - BiologicalProcess - negatively correlated with - Disease'],CHEBI:26333,MESH:D007213,"['indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'ductus arteriosus closure', 'Patent ductus arteriosus']",indomethacin,Patent ductus arteriosus,['prostaglandin'],"['negatively regulates', 'participates in', 'increases abundance of', 'negatively correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug indomethacin via its mechanism of action in treating the Disease Patent ductus arteriosus ?,prostaglandin
2762,DB13783_MESH_D012216_1,DRUGBANK:DB13783,MESH:D012216,"['MESH:C026784', 'DB:DB00328', 'UniProt:P23219', 'UniProt:P35354', 'reactome:R-HSA-2162123', 'CHEBI:26333', 'GO:0006954', 'MESH:D012216']",8,8,1,['Drug - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - negatively correlated with - BiologicalProcess - negatively correlated with - Disease'],CHEBI:26333,MESH:C026784,"['acemetacin', 'Indomethacin', 'Prostaglandin G/H synthase 1', 'Prostaglandin G/H synthase 2', 'Synthesis of Prostaglandins (PG) and Thromboxanes (TX)', 'prostaglandin', 'inflammatory response', 'Rheumatism']",acemetacin,Rheumatism,['prostaglandin'],"['has metabolite', 'negatively correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug acemetacin via its mechanism of action in treating the Disease Rheumatism ?,prostaglandin
2803,DB00419_MESH_D005776_1,DRUGBANK:DB00419,MESH:D005776,"['MESH:C059896', 'UniProt:Q16739', 'GO:0006679', 'CHEBI:36500', 'MESH:D005776']",5,4,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:36500,MESH:C059896,"['miglustat', 'Ceramide glucosyltransferase', 'glucosylceramide biosynthetic process', 'glucosylceramide', 'Gaucher Disease']",miglustat,Gaucher Disease,['glucosylceramide'],"['decreases activity of', 'positively regulates', 'increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug miglustat via its mechanism of action in treating the Disease Gaucher Disease ?,glucosylceramide
2804,DB00419_MESH_D052556_1,DRUGBANK:DB00419,MESH:D052556,"['MESH:C059896', 'UniProt:Q16739', 'GO:0006679', 'CHEBI:36500', 'HP:0000707', 'MESH:D052556']",6,5,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:36500,MESH:C059896,"['miglustat', 'Ceramide glucosyltransferase', 'glucosylceramide biosynthetic process', 'glucosylceramide', 'Abnormality of the nervous system', 'Niemann-Pick disease, type C']",miglustat,"Niemann-Pick disease, type C",['glucosylceramide'],"['decreases activity of', 'positively regulates', 'increases abundance of', 'positively correlated with', 'manifestation of']","Which biochemical entity is affected by the Drug miglustat via its mechanism of action in treating the Disease Niemann-Pick disease, type C ?",glucosylceramide
2805,DB00674_MESH_D000544_1,DRUGBANK:DB00674,MESH:D000544,"['MESH:D005702', 'UniProt:P22303', 'GO:0006581', 'CHEBI:15355', 'HP:0100543', 'MESH:D000544']",6,5,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - decreases abundance of - ChemicalSubstance - negatively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:15355,MESH:D005702,"['galantamine', 'Acetylcholinesterase', 'Acetylcholine catabolic process', 'acetylcholine', 'Cognitive impairment', 'Alzheimer Disease']",galantamine,Alzheimer Disease,['acetylcholine'],"['decreases activity of', 'positively regulates', 'decreases abundance of', 'negatively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug galantamine via its mechanism of action in treating the Disease Alzheimer Disease ?,acetylcholine
2849,DB01001_MESH_D001986_1,DRUGBANK:DB01001,MESH:D001986,"['MESH:D000420', 'UniProt:P07550', 'UniProt:B7Z2C7', 'CHEBI:17489', 'HP:4000007', 'MESH:D001986']",6,5,1,['Drug - Protein - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - positively regulates - Protein - increases abundance of - ChemicalSubstance - negatively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:17489,MESH:D000420,"['Salbutamol', 'Beta-2 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'Bronchoconstriction', 'Bronchospasm']",Salbutamol,Bronchospasm,"[""3',5'-cyclic AMP""]","['positively regulates', 'increases abundance of', 'negatively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug Salbutamol via its mechanism of action in treating the Disease Bronchospasm ?,"3',5'-cyclic AMP"
2876,DB09254_MESH_D003866_1,DRUGBANK:DB09254,MESH:D003866,"['MESH:C006919', 'UniProt:P27338', 'UniProt:P21397', 'GO:0042420', 'CHEBI:18243', 'MESH:D003866']",6,6,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - decreases abundance of - ChemicalSubstance - negatively correlated with - Disease'],CHEBI:18243,MESH:C006919,"['caroxazone', 'Amine oxidase [flavin-containing] B', 'Amine oxidase [flavin-containing] A', 'dopamine catabolic process', 'Dopamine', 'Depressive disorder']",caroxazone,Depressive disorder,['Dopamine'],"['decreases activity of', 'positively regulates', 'decreases abundance of', 'negatively correlated with']",Which biochemical entity is affected by the Drug caroxazone via its mechanism of action in treating the Disease Depressive disorder ?,Dopamine
2913,DB01344_MESH_D006947_1,DRUGBANK:DB01344,MESH:D006947,"['MESH:C003321', 'CHEBI:29103', 'MESH:D006947']",3,2,1,['Drug - ChemicalSubstance - Disease'],['Drug - decreases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:29103,MESH:C003321,"['calcium polystyrene sulfonate', 'Potassium(1+)', 'Hyperkalemia']",calcium polystyrene sulfonate,Hyperkalemia,['Potassium(1+)'],"['decreases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug calcium polystyrene sulfonate via its mechanism of action in treating the Disease Hyperkalemia ?,Potassium(1+)
2981,DB00968_MESH_D006973_1,DRUGBANK:DB00968,MESH:D006973,"['MESH:D008750', 'CHEBI:141146', 'UniProt:P08913', 'UniProt:P18089', 'UniProt:P18825', 'GO:0048242', 'GO:0048243', 'GO:0042310', 'HP:0032263', 'MESH:D006973']",10,14,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - negatively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:141146,MESH:D008750,"['methyldopa', 'α-methylnoradrenaline', 'Alpha-2A adrenergic receptor', 'Alpha-2B adrenergic receptor', 'Alpha-2C adrenergic receptor', 'epinephrine secretion', 'Norepinephrine secretion', 'vasoconstriction', 'Increased blood pressure', 'Hypertension']",methyldopa,Hypertension,['α-methylnoradrenaline'],"['has metabolite', 'increases activity of', 'negatively regulates', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug methyldopa via its mechanism of action in treating the Disease Hypertension ?,α-methylnoradrenaline
2986,DB00249_MESH_D016849_1,DRUGBANK:DB00249,MESH:D016849,"['MESH:D007065', 'CHEBI:16991', 'taxonomy:10299', 'MESH:D016849']",4,3,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - disrupts - ChemicalSubstance - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16991,MESH:D007065,"['idoxuridine', 'deoxyribonucleic acid', 'Human alphaherpesvirus 1 strain 17', 'Herpes simplex keratitis']",idoxuridine,Herpes simplex keratitis,['deoxyribonucleic acid'],"['disrupts', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug idoxuridine via its mechanism of action in treating the Disease Herpes simplex keratitis ?,deoxyribonucleic acid
2987,DB09077_MESH_D009447_1,DRUGBANK:DB09077,MESH:D009447,"['DB:DB09077', 'CHEBI:28648', 'CL:0001063', 'GO:0001913', 'GO:0097278', 'MESH:D009447']",6,6,1,['Drug - ChemicalSubstance - Cell - BiologicalProcess - Disease'],['Drug - molecularly interacts with - ChemicalSubstance - located in - Cell - location of - BiologicalProcess - negatively correlated with - Disease'],CHEBI:28648,DRUGBANK:DB09077,"['dinutuximab', ""β-D-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-D-Gal-(1→4)-β-D-Glc-(1↔1')-Cer"", 'tumor cell', 'T cell mediated cytotoxicity', 'complement-dependent cytotoxicity', 'Neuroblastoma']",dinutuximab,Neuroblastoma,"[""β-D-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-D-Gal-(1→4)-β-D-Glc-(1↔1')-Cer""]","['molecularly interacts with', 'located in', 'location of', 'negatively correlated with']",Which biochemical entity is affected by the Drug dinutuximab via its mechanism of action in treating the Disease Neuroblastoma ?,β-D-GalNAc-(1→4)-[α-Neu5Ac-(2→8)-α-Neu5Ac-(2→3)]-β-D-Gal-(1→4)-β-D-Glc-(1↔1')-Cer
3087,DB00776_MESH_D004828_1,DRUGBANK:DB00776,MESH:D004828,"['MESH:C036006', 'CHEBI:701', 'MESH:D061566', 'GO:0035725', 'GO:0019228', 'HP:0011097', 'MESH:D004828']",7,6,1,['Drug - ChemicalSubstance - GeneFamily - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - GeneFamily - positively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:701,MESH:C036006,"['oxcarbazepine', 'licarbazepine', 'Voltage-Gated Sodium Channels', 'sodium ion transmembrane transport', 'neuronal action potential', 'Epileptic spasm', 'Epilepsies, Partial']",oxcarbazepine,"Epilepsies, Partial",['licarbazepine'],"['has metabolite', 'decreases activity of', 'positively regulates', 'positively correlated with', 'positively correlated with']","Which biochemical entity is affected by the Drug oxcarbazepine via its mechanism of action in treating the Disease Epilepsies, Partial ?",licarbazepine
3098,DB00227_MESH_D006949_1,DRUGBANK:DB00227,MESH:D006949,"['MESH:D008148', 'DB:DBMET01698', 'UniProt:P04035', 'GO:0008610', 'CHEBI:18059', 'MESH:D006949']",6,5,1,['Drug - ChemicalSubstance - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - Disease'],CHEBI:18059,MESH:D008148,"['lovastatin', ""6'beta-Hydroxylovastatin"", '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'lipid biosynthetic process', 'lipid', 'Hyperlipidemia']",lovastatin,Hyperlipidemia,['lipid'],"['has metabolite', 'positively correlated with']",Which biochemical entity is affected by the Drug lovastatin via its mechanism of action in treating the Disease Hyperlipidemia ?,lipid
3099,DB00227_MESH_D006937_1,DRUGBANK:DB00227,MESH:D006937,"['MESH:D008148', 'DB:DBMET01698', 'UniProt:P04035', 'GO:0006695', 'CHEBI:16113', 'MESH:D006937']",6,5,1,['Drug - ChemicalSubstance - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - Disease'],CHEBI:16113,MESH:D008148,"['lovastatin', ""6'beta-Hydroxylovastatin"", '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'cholesterol biosynthetic process', 'cholesterol', 'Hypercholesterolemia']",lovastatin,Hypercholesterolemia,['cholesterol'],"['has metabolite', 'positively correlated with']",Which biochemical entity is affected by the Drug lovastatin via its mechanism of action in treating the Disease Hypercholesterolemia ?,cholesterol
3102,DB00227_MESH_D001161_1,DRUGBANK:DB00227,MESH:D001161,"['MESH:D008148', 'DB:DBMET01698', 'UniProt:P04035', 'GO:0006695', 'CHEBI:16113', 'HP:0002621', 'MESH:D001161']",7,6,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:16113,MESH:D008148,"['lovastatin', ""6'beta-Hydroxylovastatin"", '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'cholesterol biosynthetic process', 'cholesterol', 'Atherosclerosis', 'Arteriosclerosis']",lovastatin,Arteriosclerosis,['cholesterol'],"['has metabolite', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug lovastatin via its mechanism of action in treating the Disease Arteriosclerosis ?,cholesterol
3136,DB09561_MESH_D017674_1,DRUGBANK:DB09561,MESH:D017674,"['MESH:C029620', 'CHEBI:24838', 'HP:0100529', 'MESH:D017674']",4,3,1,['Drug - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - increases abundance of - ChemicalSubstance - correlated with - PhenotypicFeature - superclass of - Disease'],CHEBI:24838,MESH:C029620,"['sodium glycerophosphate', 'inorganic phosphate', 'Abnormal blood phosphate concentration', 'Hypophosphatemia']",sodium glycerophosphate,Hypophosphatemia,['inorganic phosphate'],"['increases abundance of', 'correlated with', 'superclass of']",Which biochemical entity is affected by the Drug sodium glycerophosphate via its mechanism of action in treating the Disease Hypophosphatemia ?,inorganic phosphate
3175,DB00845_MESH_D007918_1,DRUGBANK:DB00845,MESH:D007918,"['MESH:D002991', 'CHEBI:16991', 'taxonomy:1769', 'MESH:D007918']",4,3,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - disrupts - ChemicalSubstance - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16991,MESH:D002991,"['clofazimine', 'deoxyribonucleic acid', 'Mycobacterium leprae', 'Leprosy']",clofazimine,Leprosy,['deoxyribonucleic acid'],"['disrupts', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug clofazimine via its mechanism of action in treating the Disease Leprosy ?,deoxyribonucleic acid
3176,DB00845_MESH_D056006_1,DRUGBANK:DB00845,MESH:D056006,"['MESH:D002991', 'CHEBI:16991', 'taxonomy:1769', 'MESH:D056006']",4,3,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - disrupts - ChemicalSubstance - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16991,MESH:D002991,"['clofazimine', 'deoxyribonucleic acid', 'Mycobacterium leprae', 'Multibacillary leprosy']",clofazimine,Multibacillary leprosy,['deoxyribonucleic acid'],"['disrupts', 'in taxon', 'causes']",Which biochemical entity is affected by the Drug clofazimine via its mechanism of action in treating the Disease Multibacillary leprosy ?,deoxyribonucleic acid
3182,DB00406_MESH_D002181_1,DRUGBANK:DB00406,MESH:D002181,"['MESH:D005840', 'CHEBI:16991', 'taxonomy:237561', 'MESH:D002181']",4,3,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - disrupts - ChemicalSubstance - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16991,MESH:D005840,"['gentian violet', 'deoxyribonucleic acid', 'Candida albicans SC5314', 'Candidiasis, Vulvovaginal']",gentian violet,"Candidiasis, Vulvovaginal",['deoxyribonucleic acid'],"['disrupts', 'in taxon', 'causes']","Which biochemical entity is affected by the Drug gentian violet via its mechanism of action in treating the Disease Candidiasis, Vulvovaginal ?",deoxyribonucleic acid
3184,DB00178_MESH_D006973_1,DRUGBANK:DB00178,MESH:D006973,"['MESH:D017257', 'CHEBI:77363', 'UniProt:P12821', 'GO:0002003', 'GO:0042310', 'HP:0032263', 'MESH:D006973']",7,6,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - Protein - positively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:77363,MESH:D017257,"['ramipril', 'ramiprilat', 'Angiotensin-converting enzyme', 'angiotensin maturation', 'vasoconstriction', 'Increased blood pressure', 'Hypertension']",ramipril,Hypertension,['ramiprilat'],"['has metabolite', 'decreases activity of', 'positively regulates', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug ramipril via its mechanism of action in treating the Disease Hypertension ?,ramiprilat
3185,DB00178_MESH_D020521_1,DRUGBANK:DB00178,MESH:D020521,"['MESH:D017257', 'CHEBI:77363', 'UniProt:P12821', 'GO:0002003', 'GO:0042310', 'HP:0000822', 'MESH:D020521']",7,6,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - Protein - positively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:77363,MESH:D017257,"['ramipril', 'ramiprilat', 'Angiotensin-converting enzyme', 'angiotensin maturation', 'vasoconstriction', 'blood pressure', 'Stroke']",ramipril,Stroke,['ramiprilat'],"['has metabolite', 'decreases activity of', 'positively regulates', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug ramipril via its mechanism of action in treating the Disease Stroke ?,ramiprilat
3198,DB01551_MESH_D012220_1,DRUGBANK:DB01551,MESH:D012220,"['MESH:C014481', 'CHEBI:4575', 'UniProt:P35372', 'reactome:R-HSA-418594', 'MESH:D013373', 'GO:0006954', 'MESH:D012220']",7,6,1,['Drug - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:4575,MESH:C014481,"['dihydrocodeine', 'Dihydromorphine', 'Mu-type opioid receptor', 'G alpha (i) signalling events', 'Substance P', 'inflammatory response', 'Rhinitis']",dihydrocodeine,Rhinitis,['Dihydromorphine'],"['has metabolite', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug dihydrocodeine via its mechanism of action in treating the Disease Rhinitis ?,Dihydromorphine
3199,DB01551_MESH_D065631_1,DRUGBANK:DB01551,MESH:D065631,"['MESH:C014481', 'CHEBI:4575', 'UniProt:P35372', 'reactome:R-HSA-418594', 'MESH:D013373', 'GO:0006954', 'MESH:D065631']",7,6,1,['Drug - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:4575,MESH:C014481,"['dihydrocodeine', 'Dihydromorphine', 'Mu-type opioid receptor', 'G alpha (i) signalling events', 'Substance P', 'inflammatory response', 'Allergic rhinitis']",dihydrocodeine,Allergic rhinitis,['Dihydromorphine'],"['has metabolite', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug dihydrocodeine via its mechanism of action in treating the Disease Allergic rhinitis ?,Dihydromorphine
3200,DB01551_MESH_D010146_1,DRUGBANK:DB01551,MESH:D010146,"['MESH:C014481', 'CHEBI:4575', 'UniProt:P35372', 'reactome:R-HSA-418594', 'MESH:D013373', 'GO:0019233', 'MESH:D010146']",7,6,1,['Drug - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:4575,MESH:C014481,"['dihydrocodeine', 'Dihydromorphine', 'Mu-type opioid receptor', 'G alpha (i) signalling events', 'Substance P', 'sensory perception of pain', 'Pain']",dihydrocodeine,Pain,['Dihydromorphine'],"['has metabolite', 'positively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug dihydrocodeine via its mechanism of action in treating the Disease Pain ?,Dihydromorphine
3201,DB01551_MESH_D003371_1,DRUGBANK:DB01551,MESH:D003371,"['MESH:C014481', 'CHEBI:4575', 'UniProt:P35372', 'GO:0060004', 'MESH:D003371']",5,4,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - negatively correlated with - BiologicalProcess - positively correlated with - Disease'],CHEBI:4575,MESH:C014481,"['dihydrocodeine', 'Dihydromorphine', 'Mu-type opioid receptor', 'reflex', 'Cough']",dihydrocodeine,Cough,['Dihydromorphine'],"['has metabolite', 'increases activity of', 'negatively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug dihydrocodeine via its mechanism of action in treating the Disease Cough ?,Dihydromorphine
3202,DB01551_MESH_D003139_1,DRUGBANK:DB01551,MESH:D003139,"['MESH:C014481', 'CHEBI:4575', 'UniProt:P35372', 'reactome:R-HSA-418594', 'MESH:D013373', 'GO:0006954', 'HP:0025095', 'HP:0002315', 'MESH:D003139']",9,9,1,['Drug - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - positively correlated with - BiologicalProcess - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:4575,MESH:C014481,"['dihydrocodeine', 'Dihydromorphine', 'Mu-type opioid receptor', 'G alpha (i) signalling events', 'Substance P', 'inflammatory response', 'Sneeze', 'Headache', 'Common Cold']",dihydrocodeine,Common Cold,['Dihydromorphine'],"['has metabolite', 'positively correlated with', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug dihydrocodeine via its mechanism of action in treating the Disease Common Cold ?,Dihydromorphine
3204,DB11950_MESH_D003924_1,DRUGBANK:DB11950,MESH:D003924,"['MESH:C579035', 'UniProt:P27487', 'CHEBI:80270', 'GO:0030073', 'GO:0070091', 'HP:0003074', 'MESH:D003924']",7,7,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - negatively regulates - Protein - negatively regulates - ChemicalSubstance - negatively regulates - BiologicalProcess - positively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:80270,MESH:C579035,"['Teneligliptin', 'Dipeptidyl peptidase 4', 'Glucagon-like peptide 1', 'insulin secretion', 'glucagon secretion', 'Hyperglycemia', 'Diabetes Mellitus, Type 2']",Teneligliptin,"Diabetes Mellitus, Type 2",['Glucagon-like peptide 1'],"['negatively regulates', 'negatively regulates', 'negatively regulates', 'positively correlated with', 'positively correlated with']","Which biochemical entity is affected by the Drug Teneligliptin via its mechanism of action in treating the Disease Diabetes Mellitus, Type 2 ?",Glucagon-like peptide 1
3215,DB01095_MESH_D006937_1,DRUGBANK:DB01095,MESH:D006937,"['MESH:C065180', 'UniProt:P04035', 'GO:0006695', 'CHEBI:16113', 'MESH:D006937']",5,4,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:16113,MESH:C065180,"['fluvastatin', '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'cholesterol biosynthetic process', 'cholesterol', 'Hypercholesterolemia']",fluvastatin,Hypercholesterolemia,['cholesterol'],"['decreases activity of', 'positively regulates', 'increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug fluvastatin via its mechanism of action in treating the Disease Hypercholesterolemia ?,cholesterol
3216,DB01095_MESH_D001161_1,DRUGBANK:DB01095,MESH:D001161,"['MESH:C065180', 'UniProt:P04035', 'GO:0006695', 'CHEBI:16113', 'HP:0002621', 'MESH:D001161']",6,5,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:16113,MESH:C065180,"['fluvastatin', '3-hydroxy-3-methylglutaryl-coenzyme A reductase', 'cholesterol biosynthetic process', 'cholesterol', 'Atherosclerosis', 'Arteriosclerosis']",fluvastatin,Arteriosclerosis,['cholesterol'],"['decreases activity of', 'positively regulates', 'increases abundance of', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug fluvastatin via its mechanism of action in treating the Disease Arteriosclerosis ?,cholesterol
3259,DB04842_MESH_D012559_1,DRUGBANK:DB04842,MESH:D012559,"['MESH:D005484', 'UniProt:P14416', 'GO:0014046', 'CHEBI:18243', 'UBERON:0009834', 'UBERON:0001910', 'HP:0100543', 'HP:0030213', 'HP:0012154', 'HP:0002465', 'HP:0000741', 'HP:0000709', 'MESH:D012559']",13,17,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - GrossAnatomicalStructure - PhenotypicFeature - Disease'],['Drug - decreases activity of - Protein - positively regulates - BiologicalProcess - increases abundance of - ChemicalSubstance - located in - GrossAnatomicalStructure - correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:18243,MESH:D005484,"['fluspirilene', 'D(2) dopamine receptor', 'dopamine secretion', 'Dopamine', 'dorsolateral prefrontal cortex', 'medial forebrain bundle', 'Cognitive impairment', 'Emotional blunting', 'Anhedonia', 'Poor speech', 'Apathy', 'Psychosis', 'Schizophrenia']",fluspirilene,Schizophrenia,['Dopamine'],"['decreases activity of', 'positively regulates', 'increases abundance of', 'located in', 'correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug fluspirilene via its mechanism of action in treating the Disease Schizophrenia ?,Dopamine
3281,DB00847_MESH_D003554_1,DRUGBANK:DB00847,MESH:D003554,"['MESH:D003543', 'CHEBI:17376', 'MESH:D003554']",3,2,1,['Drug - ChemicalSubstance - Disease'],['Drug - decreases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:17376,MESH:D003543,"['mercaptamine', 'cystine', 'Cystinosis']",mercaptamine,Cystinosis,['cystine'],"['decreases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug mercaptamine via its mechanism of action in treating the Disease Cystinosis ?,cystine
3305,DB08931_MESH_D000081029_1,DRUGBANK:DB08931,MESH:D000081029,"['MESH:C542595', 'UniProt:P33402', 'CHEBI:16356', 'GO:0038060', 'GO:0042311', 'GO:0060087', 'MESH:D000081029']",7,6,1,['Drug - Protein - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - increases activity of - Protein - increases abundance of - ChemicalSubstance - participates in - BiologicalProcess - prevents - Disease'],CHEBI:16356,MESH:C542595,"['riociguat', 'Guanylate cyclase soluble subunit alpha-2', ""cyclic guanosine 3',5' monophosphate"", 'nitric oxide-cGMP-mediated signaling pathway', 'vasodilation', 'Relaxation of vascular associated smooth muscle', 'Pulmonary arterial hypertension']",riociguat,Pulmonary arterial hypertension,"[""cyclic guanosine 3',5' monophosphate""]","['increases activity of', 'increases abundance of', 'participates in', 'prevents']",Which biochemical entity is affected by the Drug riociguat via its mechanism of action in treating the Disease Pulmonary arterial hypertension ?,"cyclic guanosine 3',5' monophosphate"
3325,DB12466_MESH_D007251_1,DRUGBANK:DB12466,MESH:D007251,"['MESH:C462182', 'CHEBI:170009', 'UniProt:Q809M3', 'GO:0039694', 'taxonomy:11309', 'MESH:D007251']",6,5,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - OrganismTaxon - Disease'],['Drug - has metabolite - ChemicalSubstance - negatively regulates - Protein - positively regulates - BiologicalProcess - in taxon - OrganismTaxon - causes - Disease'],CHEBI:170009,MESH:C462182,"['favipiravir', 'favipiravir-RTP', 'RNA-directed RNA polymerase catalytic subunit', 'Viral RNA genome replication', 'Influenza virus', 'Influenza, Human']",favipiravir,"Influenza, Human",['favipiravir-RTP'],"['has metabolite', 'negatively regulates', 'positively regulates', 'in taxon', 'causes']","Which biochemical entity is affected by the Drug favipiravir via its mechanism of action in treating the Disease Influenza, Human ?",favipiravir-RTP
3362,DB01592_MESH_D018798_1,DRUGBANK:DB01592,MESH:D018798,"['MESH:D007501', 'CHEBI:18248', 'GO:0055072', 'MESH:D018798']",4,3,1,['Drug - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - increases abundance of - ChemicalSubstance - correlated with - BiologicalProcess - negatively correlated with - Disease'],CHEBI:18248,MESH:D007501,"['iron', 'iron atom', 'iron ion homeostasis', 'Iron deficiency anemia']",iron,Iron deficiency anemia,['iron atom'],"['increases abundance of', 'correlated with', 'negatively correlated with']",Which biochemical entity is affected by the Drug iron via its mechanism of action in treating the Disease Iron deficiency anemia ?,iron atom
3394,DB00608_MESH_D016780_1,DRUGBANK:DB00608,MESH:D016780,"['MESH:D002738', 'MESH:D006418', 'CHEBI:36161', 'taxonomy:5855', 'MESH:D016780']",5,5,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - molecularly interacts with - ChemicalSubstance - disrupts - OrganismTaxon - causes - Disease'],CHEBI:36161,MESH:D002738,"['chloroquine', 'Heme', 'hematin', 'Plasmodium vivax', 'Vivax malaria']",chloroquine,Vivax malaria,['hematin'],"['molecularly interacts with', 'disrupts', 'causes']",Which biochemical entity is affected by the Drug chloroquine via its mechanism of action in treating the Disease Vivax malaria ?,hematin
3397,DB00608_MESH_D016778_1,DRUGBANK:DB00608,MESH:D016778,"['MESH:D002738', 'MESH:D006418', 'CHEBI:36161', 'taxonomy:5833', 'MESH:D016778']",5,5,1,['Drug - ChemicalSubstance - OrganismTaxon - Disease'],['Drug - molecularly interacts with - ChemicalSubstance - disrupts - OrganismTaxon - causes - Disease'],CHEBI:36161,MESH:D002738,"['chloroquine', 'Heme', 'hematin', 'Plasmodium falciparum', 'Falciparum malaria']",chloroquine,Falciparum malaria,['hematin'],"['molecularly interacts with', 'disrupts', 'causes']",Which biochemical entity is affected by the Drug chloroquine via its mechanism of action in treating the Disease Falciparum malaria ?,hematin
3408,DB09065_MESH_D015658_2,DRUGBANK:DB09065,MESH:D015658,"['MESH:D000069547', 'InterPro:IPR001128\ufeff', 'GO:0042178', 'CHEBI:22587', 'MESH:D015658']",5,4,1,['Drug - GeneFamily - BiologicalProcess - ChemicalSubstance - Disease'],['Drug - negatively regulates - GeneFamily - positively regulates - BiologicalProcess - decreases abundance of - ChemicalSubstance - negatively correlated with - Disease'],CHEBI:22587,MESH:D000069547,"['cobicistat', 'Cytochrome P450', 'xenobiotic catabolic process', 'antiviral agent', 'Human immunodeficiency virus infection']",cobicistat,Human immunodeficiency virus infection,['antiviral agent'],"['negatively regulates', 'positively regulates', 'decreases abundance of', 'negatively correlated with']",Which biochemical entity is affected by the Drug cobicistat via its mechanism of action in treating the Disease Human immunodeficiency virus infection ?,antiviral agent
3412,DB00437_MESH_D006073_1,DRUGBANK:DB00437,MESH:D006073,"['MESH:D000493', 'UniProt:P47989', 'reactome:R-HSA-74259', 'CHEBI:27226', 'MESH:D006073']",5,4,1,['Drug - Protein - Pathway - ChemicalSubstance - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:27226,MESH:D000493,"['allopurinol', 'Xanthine dehydrogenase/oxidase', 'Purine catabolism', 'uric acid', 'Gout']",allopurinol,Gout,['uric acid'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug allopurinol via its mechanism of action in treating the Disease Gout ?,uric acid
3413,DB00437_MESH_D015210_1,DRUGBANK:DB00437,MESH:D015210,"['MESH:D000493', 'UniProt:P47989', 'reactome:R-HSA-74259', 'CHEBI:27226', 'HP:0001854', 'MESH:D015210']",6,5,1,['Drug - Protein - Pathway - ChemicalSubstance - PhenotypicFeature - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:27226,MESH:D000493,"['allopurinol', 'Xanthine dehydrogenase/oxidase', 'Purine catabolism', 'uric acid', 'Podagra', 'Articular gout']",allopurinol,Articular gout,['uric acid'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug allopurinol via its mechanism of action in treating the Disease Articular gout ?,uric acid
3414,DB00437_MESH_D033461_1,DRUGBANK:DB00437,MESH:D033461,"['MESH:D000493', 'UniProt:P47989', 'reactome:R-HSA-74259', 'CHEBI:27226', 'MESH:D033461']",5,4,1,['Drug - Protein - Pathway - ChemicalSubstance - Disease'],['Drug - negatively regulates - Protein - participates in - Pathway - increases abundance of - ChemicalSubstance - positively correlated with - Disease'],CHEBI:27226,MESH:D000493,"['allopurinol', 'Xanthine dehydrogenase/oxidase', 'Purine catabolism', 'uric acid', 'Hyperuricemia']",allopurinol,Hyperuricemia,['uric acid'],"['negatively regulates', 'participates in', 'increases abundance of', 'positively correlated with']",Which biochemical entity is affected by the Drug allopurinol via its mechanism of action in treating the Disease Hyperuricemia ?,uric acid
3458,DB00251_MESH_D002181_1,DRUGBANK:DB00251,MESH:D002181,"['MESH:C037815', 'UniProt:P10613', 'GO:0006696', 'CHEBI:16933', 'GO:0030445', 'MESH:D002463', 'taxonomy:237561', 'MESH:D002181']",8,7,1,['Drug - Protein - BiologicalProcess - ChemicalSubstance - CellularComponent - PhenotypicFeature - OrganismTaxon - Disease'],['Drug - negatively regulates - Protein - positively regulates - BiologicalProcess - produces - ChemicalSubstance - located in - CellularComponent - regulates - PhenotypicFeature - in taxon - OrganismTaxon - causes - Disease'],CHEBI:16933,MESH:C037815,"['terconazole', 'Lanosterol 14-alpha-demethylase', 'ergosterol biosynthetic process', 'ergosterol', 'yeast-form cell wall', 'Cell Membrane Permeability', 'Candida albicans SC5314', 'Candidiasis, Vulvovaginal']",terconazole,"Candidiasis, Vulvovaginal",['ergosterol'],"['negatively regulates', 'positively regulates', 'produces', 'located in', 'regulates', 'in taxon', 'causes']","Which biochemical entity is affected by the Drug terconazole via its mechanism of action in treating the Disease Candidiasis, Vulvovaginal ?",ergosterol
3674,DB00153_MESH_D014808_1,DRUGBANK:DB00153,MESH:D014808,"['DB:DB00153', 'CHEBI:86320', 'UniProt:P11473', 'GO:0070561', 'MESH:D014808']",5,4,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:86320,DRUGBANK:DB00153,"['ergocalciferol', '1α,25-dihydroxyvitamin D2', 'Vitamin D3 receptor', 'vitamin D receptor signaling pathway', 'Vitamin D deficiency']",ergocalciferol,Vitamin D deficiency,"['1α,25-dihydroxyvitamin D2']","['has metabolite', 'increases activity of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug ergocalciferol via its mechanism of action in treating the Disease Vitamin D deficiency ?,"1α,25-dihydroxyvitamin D2"
3675,DB00153_MESH_D006996_1,DRUGBANK:DB00153,MESH:D006996,"['DB:DB00153', 'CHEBI:86320', 'UniProt:P11473', 'GO:0070561', 'GO:0070509', 'MESH:D006996']",6,5,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:86320,DRUGBANK:DB00153,"['ergocalciferol', '1α,25-dihydroxyvitamin D2', 'Vitamin D3 receptor', 'vitamin D receptor signaling pathway', 'Calcium ion import', 'Hypocalcemia']",ergocalciferol,Hypocalcemia,"['1α,25-dihydroxyvitamin D2']","['has metabolite', 'increases activity of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug ergocalciferol via its mechanism of action in treating the Disease Hypocalcemia ?,"1α,25-dihydroxyvitamin D2"
3676,DB00153_MESH_D007011_1,DRUGBANK:DB00153,MESH:D007011,"['DB:DB00153', 'CHEBI:86320', 'UniProt:P11473', 'GO:0070561', 'GO:0070509', 'HP:0002901', 'MESH:D007011']",7,6,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - positively regulates - BiologicalProcess - negatively correlated with - PhenotypicFeature - positively correlated with - Disease'],CHEBI:86320,DRUGBANK:DB00153,"['ergocalciferol', '1α,25-dihydroxyvitamin D2', 'Vitamin D3 receptor', 'vitamin D receptor signaling pathway', 'Calcium ion import', 'Hypocalcemia', 'Hypoparathyroidism']",ergocalciferol,Hypoparathyroidism,"['1α,25-dihydroxyvitamin D2']","['has metabolite', 'increases activity of', 'positively regulates', 'negatively correlated with', 'positively correlated with']",Which biochemical entity is affected by the Drug ergocalciferol via its mechanism of action in treating the Disease Hypoparathyroidism ?,"1α,25-dihydroxyvitamin D2"
3677,DB00153_MESH_D012279_1,DRUGBANK:DB00153,MESH:D012279,"['DB:DB00153', 'CHEBI:86320', 'UniProt:P11473', 'GO:0070561', 'GO:0030282', 'MESH:D012279']",6,5,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:86320,DRUGBANK:DB00153,"['ergocalciferol', '1α,25-dihydroxyvitamin D2', 'Vitamin D3 receptor', 'vitamin D receptor signaling pathway', 'bone mineralization', 'Rickets']",ergocalciferol,Rickets,"['1α,25-dihydroxyvitamin D2']","['has metabolite', 'increases activity of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug ergocalciferol via its mechanism of action in treating the Disease Rickets ?,"1α,25-dihydroxyvitamin D2"
3678,DB00153_MESH_D053098_1,DRUGBANK:DB00153,MESH:D053098,"['DB:DB00153', 'CHEBI:86320', 'UniProt:P11473', 'GO:0070561', 'GO:0030282', 'MESH:D053098']",6,5,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:86320,DRUGBANK:DB00153,"['ergocalciferol', '1α,25-dihydroxyvitamin D2', 'Vitamin D3 receptor', 'vitamin D receptor signaling pathway', 'bone mineralization', 'Familial x-linked hypophosphatemic vitamin D refractory rickets']",ergocalciferol,Familial x-linked hypophosphatemic vitamin D refractory rickets,"['1α,25-dihydroxyvitamin D2']","['has metabolite', 'increases activity of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug ergocalciferol via its mechanism of action in treating the Disease Familial x-linked hypophosphatemic vitamin D refractory rickets ?,"1α,25-dihydroxyvitamin D2"
3679,DB00153_MESH_D001361_1,DRUGBANK:DB00153,MESH:D001361,"['DB:DB00153', 'CHEBI:86320', 'UniProt:P11473', 'GO:0070561', 'MESH:D001361']",5,4,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - increases activity of - Protein - positively regulates - BiologicalProcess - negatively correlated with - Disease'],CHEBI:86320,DRUGBANK:DB00153,"['ergocalciferol', '1α,25-dihydroxyvitamin D2', 'Vitamin D3 receptor', 'vitamin D receptor signaling pathway', 'Vitamin deficiency']",ergocalciferol,Vitamin deficiency,"['1α,25-dihydroxyvitamin D2']","['has metabolite', 'increases activity of', 'positively regulates', 'negatively correlated with']",Which biochemical entity is affected by the Drug ergocalciferol via its mechanism of action in treating the Disease Vitamin deficiency ?,"1α,25-dihydroxyvitamin D2"
3682,DB00389_MESH_D006980_1,DRUGBANK:DB00389,MESH:D006980,"['MESH:D002231', 'CHEBI:50673', 'UniProt:P07202', 'GO:0006590', 'MESH:D006980']",5,4,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - Protein - participates in - BiologicalProcess - positively correlated with - Disease'],CHEBI:50673,MESH:D002231,"['carbimazole', 'methimazole', 'Thyroid peroxidase', 'thyroid hormone generation', 'Hyperthyroidism']",carbimazole,Hyperthyroidism,['methimazole'],"['has metabolite', 'decreases activity of', 'participates in', 'positively correlated with']",Which biochemical entity is affected by the Drug carbimazole via its mechanism of action in treating the Disease Hyperthyroidism ?,methimazole
3683,DB00389_MESH_D006111_1,DRUGBANK:DB00389,MESH:D006111,"['MESH:D002231', 'CHEBI:50673', 'UniProt:P07202', 'GO:0006590', 'HP:0000836', 'MESH:D006111']",6,5,1,['Drug - ChemicalSubstance - Protein - BiologicalProcess - PhenotypicFeature - Disease'],['Drug - has metabolite - ChemicalSubstance - decreases activity of - Protein - participates in - BiologicalProcess - positively correlated with - PhenotypicFeature - manifestation of - Disease'],CHEBI:50673,MESH:D002231,"['carbimazole', 'methimazole', 'Thyroid peroxidase', 'thyroid hormone generation', 'Hyperthyroidism', ""Graves' disease""]",carbimazole,Graves' disease,['methimazole'],"['has metabolite', 'decreases activity of', 'participates in', 'positively correlated with', 'manifestation of']",Which biochemical entity is affected by the Drug carbimazole via its mechanism of action in treating the Disease Graves' disease ?,methimazole
3787,DB00187_MESH_D001281_1,DRUGBANK:DB00187,MESH:D001281,"['MESH:C036604', 'UniProt:P08588', 'InterPro:IPR030672', 'CHEBI:17489', 'GO:0070509', 'GO:0086003', 'MESH:D001281']",7,6,1,['Drug - Protein - GeneFamily - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - decreases activity of - Protein - increases activity of - GeneFamily - increases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - positively correlated with - Disease'],CHEBI:17489,MESH:C036604,"['esmolol', 'Beta-1 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'Calcium ion import', 'Cardiac muscle cell contraction', 'Atrial fibrillation']",esmolol,Atrial fibrillation,"[""3',5'-cyclic AMP""]","['decreases activity of', 'increases activity of', 'increases abundance of', 'positively regulates', 'positively correlated with']",Which biochemical entity is affected by the Drug esmolol via its mechanism of action in treating the Disease Atrial fibrillation ?,"3',5'-cyclic AMP"
3788,DB00187_MESH_D013617_1,DRUGBANK:DB00187,MESH:D013617,"['MESH:C036604', 'UniProt:P08588', 'InterPro:IPR030672', 'CHEBI:17489', 'GO:0070509', 'GO:0086003', 'MESH:D013617']",7,6,1,['Drug - Protein - GeneFamily - ChemicalSubstance - BiologicalProcess - Disease'],['Drug - decreases activity of - Protein - increases activity of - GeneFamily - increases abundance of - ChemicalSubstance - positively regulates - BiologicalProcess - positively correlated with - Disease'],CHEBI:17489,MESH:C036604,"['esmolol', 'Beta-1 adrenergic receptor', 'Adenylate cyclase', ""3',5'-cyclic AMP"", 'Calcium ion import', 'Cardiac muscle cell contraction', 'Supraventricular tachycardia']",esmolol,Supraventricular tachycardia,"[""3',5'-cyclic AMP""]","['decreases activity of', 'increases activity of', 'increases abundance of', 'positively regulates', 'positively correlated with']",Which biochemical entity is affected by the Drug esmolol via its mechanism of action in treating the Disease Supraventricular tachycardia ?,"3',5'-cyclic AMP"
